 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422571] u d y Pr oce d ures b y Visit .......................................................................................... 3 2  
8. 2. Efficac y E val uati o ns  ................................................................................................... 3 4  
8. 3. Safet y E val uati o ns ...................................................................................................... 3 6  
9. A D V E R S E E V E N T R E P O R TI N G  ............................................................................ 3 8  
9. 1. A d verse E ve nt Classificati o n Defi niti o ns ................................................................... 3 9  
9. 2. M o nit ori n g of A d verse E ve nts  .................................................................................... 4 1  
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422572] u g(s) ....................................................................... [ADDRESS_422573] u g Acc o u nta bilit y ................................................................................................... 5 2  
1 3. E T HI C A L A S P E C T S  ................................................................................................. 5 3  
1 3. 1. I n vesti gat or Res p o nsi bilities ....................................................................................... 5 3  
1 3. 2. I nstit uti o nal Re vie w B oar d (I R B) a n d Researc h Et hics C o m mittee ( R E C) ............... 5 3  
1 3. 3. I nf or me d C o nse nt ....................................................................................................... 5 3  
1 4. A D MI NI S T R A TI V E R E Q UI R E M E N T S  .................................................................. 5 4  
1 4. 1. Pr ot oc ol M o dificati o ns ............................................................................................... 5 4  
1 4. 2. Re g ulat or y D oc u me ntati o n  ......................................................................................... 5 4  
1 4. 3. Rec or d Rete nti o n ........................................................................................................ 5 4  
1 4. 4. Electr o nic Case Re p ort F or m  ...................................................................................... 5 5  
1 4. 5. Ter mi nati o n  ................................................................................................................. 5 5  
1 4. 6. Data a n d Safet y M o nit ori n g Pla n  ............................................................................... 5 6  
1 4. 7. M o nit ori n g .................................................................................................................. 5 6  
1 4. 8. Data Q ualit y Ass ura nce  .............................................................................................. 5 6  
1 4. 9. O n -Site A u dits  ............................................................................................................ 5 7  
1 4. 1 0.  Use of I nf or mati o n a n d P u blicati o n ............................................................................ 5 7  
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 5   1 5. R E F E R E N C E S  ........................................................................................................... 5 8  
 
LI S T O F T A B L E S  
Ta ble  1:  Ti me a n d E ve nts Sc he d ule .......................................................................................... 2 2  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 7 Secti o n(s)  Descri pti o n of C h a n ges  R ati o n ale 
F ull A n al ysis Set ( F A S):   T he f ull a nal ysis set will 
i ncl u de all s u bjects w h o are ra n d o mize d, recei ve st u d y 
dr u g, ha ve a baseli ne defi niti ve verti g o meas ure me nt 
f or t he 4-wee k lea d -i n peri o d a n d at least o ne p ost-baseli ne dail y diar y e ntr y.  T he pri mar y a nal ysis f or t he 
pri mar y e n d p oi nt of D V D will be c o n d ucte d usi n g t he 
F A S.  S u bjects will be i ncl u de d i n t he treat me nt gr o u p t o w hic h t he y were ra n d o mize d re gar dless of t he act ual 
st u d y dr u g recei ve d. 
Is: F ull A n al ysis Set ( F A S) :  T he f ull a nal ysis set will 
i ncl u de all s u bjects w h o are ra n d o mize d, recei ve st u d y 
dr u g, ha ve a baseli ne defi niti ve verti g o meas ure me nt f or t he 4-wee k lea d -i n peri o d a n d at least o ne p ost-
baseli ne dail y diar y e n tr y f or Wee k [ADDRESS_422574] u g 
recei ve d. 
Per Pr ot oc ol A n al ysis Set  defi niti o n  
Was:  
Per Pr ot oc ol A n al ysis Set:   T he per pr ot oc ol a nal ysis 
set will i ncl u de all s u bjects w h o are ra n d o mize d, 
recei ve st u d y dr u g, meet eli gi bilit y criteria, ha ve n o 
maj or pr ot oc ol de viati o ns,  a n d ha ve a baseli ne a n d at least o ne 4-wee k defi niti ve verti g o meas ure me n t p ost-
baseli ne, i.e. at least o ne p ost -baseli ne dail y diar y 
e ntr y.   
Is: 
Per Pr ot oc ol A n al ysis Set:   T he per pr ot oc ol a nal ysis 
set will i ncl u de all s u bjects w h o are ra n d o mize d, recei ve st u d y dr u g, meet eli gi bilit y criteria, ha ve n o 
maj or pr ot oc ol de viati o ns,  a n d ha ve a baseli ne 
defi niti ve verti g o me as ure me nt  a n d at least o ne p ost -baseli ne d ail y di ar y e ntr y wit hi n Wee k 9 t hr o u g h 1 2 . 
I nte nt t o Tre at A n al ysis Set: 
Was:  I nte nt-t o-Treat A nal ysis Set (I T T):  T he I T T a nal ysis 
set will i ncl u de all ra n d o mize d s u bjects w h o recei ve 
st u d y dr u g.  S u bjects will be i ncl u de d i n t he treat me nt reflecti n g pri mar y a nal ysis is at Wee k 
1 2 [t he 4- wee k ( 2 8 
da y) i nter val fr o m Wee k 9 t hr o u g h 
Wee k 1 2 ] a n d 
clarificati o n o n w he n t he I T T 
p o p ulati o n will be 
use d.   
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 1 0 Secti o n(s)  Descri pti o n of C h a n ges  R ati o n ale 
w here a defi niti ve verti g o e pis o de was rec or de d 
di vi de d b y t he n u m ber of n o n- missi n g diar y e ntries 
f or t he rele va nt i nter val 
• Se verit y of verti g o e pis o des as meas ure d b y t he
mea n Verti g o Sc ore d uri n g eac h 4- wee k st u d yi nter val ( Wee k 1 t hr o u g h Wee k 4) a n d ( Wee k 5
t hr o u g h 8).
• A vera ge dail y c o u nt of verti g o e pis o des d uri n g
eac h 4- wee k st u d y i nter val ( Wee k 1 t hr o u g h Wee k4) a n d ( Wee k 5 t hr o u g h Wee k 8)
• T he n u m ber of da ys Sic k at h o me or Be dri d de n as a
c o nse q ue nce of verti g o d uri n g eac h 4- wee k st u d yi nter val ( Wee k 1 t hr o u g h Wee k 4) a n d ( Wee k 5t hr o u g h Wee k 8)
• T he n u m ber of defi niti ve verti g o da ys ( D V D)
d uri n g eac h [ADDRESS_422575] u d y i nter val ( Wee k 1 t hr o u g hWee k 4) a n d ( Wee k 5 t hr o u g h Wee k 8)
Is: 
• T he c ha n ge fr o m baseli ne i n verti g o fre q ue nc y
( V F) at Wee k 8, w here verti g o fre q ue nc y is defi ne d
as t he n u m ber of D V Ds rec or de d d uri n g t he 4-
wee k i nter val di vi de d b y t he n u m ber of n o n-missi n g diar y e ntries f or t he rele va nt i nter val
• Se verit y of verti g o e pis o des as meas ure d b y t he
Me a n Se verit y  Verti g o Sc ore ( M S V S ) at Wee k 8
• A vera ge dail y c o u nt of verti g o e pis o des at  Wee k 8
• T he [ADDRESS_422576] u d y i nter val  (i.e., Wee k 4,
Wee k 8, Wee k 1 2 )
• T he 2 8- d a y a ver a ge  defi niti ve verti g o da ys ( D V D)
at  Wee k 8
Ne w Te xt:  
• Occ urre nce of N or m al acti vit y, Sli g ht li mit ati o n,
M o der ate li mit ati o n, Sic k at h o me, a n dBe dri d de n e ve nts as a c o nse q ue nce of verti g o at
Wee k 4, Wee k 8, a n d Wee k [ADDRESS_422577] orat or y  e n d p oi nts. 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 1 1 Secti o n(s)  Descri pti o n of C h a n ges  R ati o n ale 
1 1. 5. 4 A nal ytic 
met h o ds f or 
Efficac y Re vise d Secti o n ( mi x of pre vi o us a n d ne w te xt). 
T he pri m ar y effic ac y e n d p oi nt, t he 2 8 - d a y a ver a ge 
D V D at Wee k 1 2 (t he 4- wee k i nter v al fr o m Wee k 9 
t hr o u g h Wee k 1 2), will be c o m p are d bet wee n O T O-[ADDRESS_422578] ace b o at t he 2-t aile d, 0. 0 5 al p h a le vel 
usi n g a Ne g ati ve Bi n o mi al m o del. T his m o del will 
i ncl u de fi xed effects f or r a n d o mize d tre at me nt gr o u p ( O T O - [ADDRESS_422579] ace b o) a n d se x ( m ale vs. 
fe m ale), wit h t he [ADDRESS_422580] u d y is f ull a nal ysis set ( F A S).  S u bjects will be i ncl u de d i n t he treat me nt gr o u p t o w hic h t he y were 
ra n d o mize d re gar dless of t he act ual st u d y dr u g 
recei ve d. 
T he pri mar y e n d p oi nt a nal ysis als o will be c o n d ucte d 
usi n g per- pr ot oc ol a n d I T T a nal ysis sets as se nsiti vit y 
a nal yses.   
T he ke y  sec o n dar y efficac y e n d p oi nt of t he Me a n 
Se verit y Verti g o Sc ore ( M S V S) f or Wee k 1 2  ( Wee k 
9 t hr o u g h Wee k 1 2) will be a n al yze d usi n g a n A N C O V A m o del wit h fi xe d effects of r a n d o mize d 
tre at me nt, gr o u p ( O T O- [ADDRESS_422581] ace b o) a n d se x 
( m ale vs. fe m ale), wit h t he s u bject’s a ver a ge me a n se verit y verti g o sc ore at le a d-i n peri o d as a 
c o v ari ate. 
T he ke y  sec o n dar y e n d p oi nt of t he 2 8- d a y a ver a ge of 
n u m ber of da ys Sic k at h o me or Be dri d de n ( D S B ) as a 
c o nse q ue nce of verti g o at Wee k 1 2 will be c o m pare d 
bet wee n t he treat me nt gr o u ps usi n g usi n g t he s a me Ne g ati ve Bi n o mi al m o del as s pecifie d f or t he 
pri m ar y a n al ysis a n d usi n g t he 2 8- d a y a ver a ge 
Le a d -i n D S B as a c o v ari ate.  T he m o del will i ncl u de fi xe d effects f or ra n d o mize d treat me nt gr o u p ( O T O-
[ADDRESS_422582] b o) a n d  se x ( male vs. fe male).   
T he ke y sec o n d ar y e n d p oi nts of perce nt of s u bjects 
ac hie vi n g a 7 5 % a n d a 1 0 0 % (i.e., c o u nt of zer o) 
re d ucti o n fr o m b ase li ne i n [ADDRESS_422583] orat pr y a nal yses a n d t he 
gate- kee pi n g 
pr oce d ure t hat is pr o vi de d i n t he 
S A P Versi o n 2. 0. 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 1 2 Secti o n(s)  Descri pti o n of C h a n ges  R ati o n ale 
9 5 % CI ar o u n d t he ris k differe nce will als o be 
pr o vi de d.  
T he sec o n dar y efficac y e n d p oi nt of c ha n ge fr o m 
baseli ne i n verti g o fre q ue nc y ( V F) at Wee k 1 2 (t he 4-wee k i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2), will be 
a nal yze d usi n g a n A N C O V A m o del wit h tre at me nt 
as a fi xe d effect a n d se x as fi xe d effects wit h t he le a d-i n peri o d V F as a c o v ari ate.   
T he sec o n dar y efficac y e n d p oi nt of a vera ge dail y c o u nt 
of verti g o e pis o des d uri n g 4- wee k st u d y i nter val ( Wee k 9 t hr o u g h Wee k 1 2) will be usi n g t he A N C O V A 
m o del s pecifie d f or t he sec o n d ar y effic ac y e n d p oi nt 
of c h a n ge fr o m b aseli ne i n V F at Wee k [ADDRESS_422584]’s A ver a ge D ail y Verti g o C o u nt ( A D V C) 
at le a d-i n peri o d as a c o v ari ate .    
Alter nati ve m o dels will be pre -s pecifie d i n t he S A P 
s h o ul d certai n ass u m pti o ns re gar di n g data a n d m o dels 
d o n ot h ol d.  I n a d diti o n, t he S A P will i ncl u de pre-
s pecifie d data tra nsf or mati o ns s h o ul d e val uati o n of t he resi d uals s u g gest a data tra nsf or mati o n is m ore 
s uita ble. 
If t he pri mar y e n d p oi nt c o m paris o n bet wee n t he t w o 
treat me nt gr o u ps is statisticall y si g nifica nt i n fa v or of 
O T O - 1 0 4 t he n a cl ose d testi n g, gate- kee pi n g pr oce d ure 
will be use d t o c o m pare t he f oll o wi n g sec o n dar y efficac y e n d p oi nts se q ue ntiall y:  
1. Se verit y of verti g o e pis o des as meas ure d b y t he
mea n Verti g o Sc ore at Wee k 1 2 (t he 4 -wee k ( 2 8 -
da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2)
2. T he 2 8- d a y a ver a ge  n u m ber of da ys Sic k at h o me
or Be dri d de n as a c o nse q ue nce of verti g o at Wee k1 2 (t he 4- wee k ( 2 8- da y) i nter val fr o m Wee k 9
t hr o u g h Wee k 1 2)
3. Perce nt of s u bjects ac hie vi n g a 7 5 % re d ucti o n
fr o m b aseli ne i n 2 8- d a y a ver a ge D V D at Wee k1 2 .
4. Perce nt of s u bjects ac hie vi n g a 1 0 0 % re d ucti o n
fr o m b aseli ne (i.e., c o u nt of zer o) i n 2 8 - d a ya ver a ge D V D at Wee k 1 2.
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 1 3 Secti o n(s)  Descri pti o n of C h a n ges  R ati o n ale 
I n t his pr oce d ure, if t he first sec o n dar y e n d p oi nt 
c o m paris o n bet wee n t he t w o treat me nt gr o u ps is 
statisticall y si g nifica nt i n fa v or of O T O- [ADDRESS_422585] atistic all y si g nific a nt differe nce 
bet wee n gr o u ps i n f a v or of O T O- 1 0 4, t he g ate-
kee pi n g pr oce d ure e n ds a n d a n y s u bse q ue nt ke y sec o n d ar y e n d p oi nt p-v al ues will be c o nsi dere d as a 
n o mi n al p - v al ue(s).  
T he g ate- kee pi n g pr oce d ure c o ntr ols t he T y pe I 
err or f or t he f o ur pl a n ne d c o m p aris o ns  a n d, 
t heref ore, t here will be n o α s pe n di n g pe n alt y 
ass oci ate d wit h t he pl a n ne d ke y  sec o n d ar y c o m p aris o ns.  
T he re m ai ni n g sec o n d ar y e n d p oi nts c o m p aris o ns 
will n ot f oll o w t he g ate -kee pi n g pr oce d ure a n d, t heref ore, t he re p orte d p-v al ues will be re p orte d as 
n o mi n al p - v al ues.  T hese a n al yses will be c o n d ucte d 
usi n g t he F A S o nl y.  
All effic ac y h y p ot hesis tests will be 2 -si de d a n d 
perf or me d at α = 0. 0 5 si g nific a nce le vel, u nless 
ot her wise s pecifi d i n t he S A P.  
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422586] u d y. 
I will use o nl y t he i nf or me d c o nse nt f or m a p pr o ve d b y Ot o n o m y, I nc. ( hereafter, “t he S p o ns or”) 
or its re prese ntati ve a n d a p pr o ve d b y t he I nstit uti o nal Re vie w B oar d (I R B) or Researc h Et hics 
C o m mittee  (R E C ) res p o nsi ble f or t his st u d y a n d will f ulfill all res p o nsi bilities f or s u b mitti n g perti ne nt i nf or mati o n t o t he I R B or R E C res p o nsi ble f or t his st u d y.  I will ass ure t hat eac h 
s u bject e nr olle d i nt o t he trial, or le gall y a ut h orize d re prese ntati ve, rea ds, u n dersta n ds, a n d si g ns 
t he a p pr o priate versi o n of t he i nf or me d c o nse nt. I a gree t hat t he S p o ns or or its re prese ntati ves s hall ha ve access t o a n y ori gi nal s o urce d oc u me nts t o verif y data ca pt ure d f or t his cli nical trial. 
I f urt her a gree n ot t o ori gi nate or use t he na me of t he S p o ns or a n d/ or O T O- [ADDRESS_422587] o yees, i n a n y p u blicit y, ne ws release or ot her p u blic a n n o u nce me nt, writte n or oral, w het her t o t he p u blic, press or ot her wise, relati n g t o t his pr ot oc ol, t o a n y a me n d me nt heret o, or t o t he 
perf or ma nce here u n der, wit h o ut t he pri or writte n c o nse nt of t he S p o ns or. 
  
   
I n vesti gat or's Si g nat ure  Date  
Na me of I n vesti gat or (ty pe d or pri nte d) 
 
          
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422588] ( St u d y Dr u g) P T A  P ure T o ne A vera ge  
P GI C  
Q M P  Patie nt Gl o bal I m pressi o n of C ha n ge  Q ualifie d Me dical Pr ofessi o nal  
R E C  Researc h Et hics C o m mittee  
S A E  Seri o us A d verse E ve nt  S A P  Statistical A nal ysis Pla n  
S F -[ADDRESS_422589] u g Dicti o nar y  
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 1 7 S Y N O P SI S  
N A M E O F S P O N S O R/ C O M P A N Y : Ot o n o m y, I nc.  
N A M E O F FI NI S H E D P R O D U C T : 
N A M E O F A C TI V E I N G R E DI E N T( S) : O T O- 1 0 4  
De x a met has o ne  
Pr ot oc ol N o.:  [ADDRESS_422590] u d y:  A pr os pecti ve, ra n d o mize d, d o u ble bli n d, place b o -c o ntr olle d, m ultice nter, P hase [ADDRESS_422591] u d y of O T O-1 0 4 gi ve n as a si n gle i ntrat y m pa nic i njecti o n i n s u bjects wit h u nilateral Me niere’s disease.  
St u d y Ce nter(s):   T his st u d y wi ll be c o n d ucte d at a p pr o xi matel y [ADDRESS_422592] u d y Peri o d:  A p pr o xi matel y 1. 5 years  P h ase of De vel o p me nt:  [ADDRESS_422593] u d y Desi g n:  
T his is a ra n d o mize d, d o u ble bli n d, place b o -c o ntr olle d, m ultice nter [ADDRESS_422594] b o 
usi n g a 1: [ADDRESS_422595] u d y O bjecti ve s: 
Pri mar y : T o i n vesti gate t he efficac y of O T O-1 0 4 i n s u bjects wit h Me niere’s disease, as meas ure d b y t he 
n u m ber of defi niti ve verti g o da ys ( D V D) at Wee k 1 2 (t he 4 -wee k i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2).  
Sec o n dar y :  T o i n vesti gate t he safet y pr ofile of O T O-1 0 4 i n s u bjects wit h Me niere’s disease.  
Met h o d s: 
T he d urati o n of t he st u d y f or eac h s u bject will be a p pr o xi matel y 1 6  wee ks, i ncl u di n g a 4 -wee k lea d -i n peri o d 
bef ore d osi n g (a si n gle  i njecti o n), f oll o we d b y a 12- wee k f oll o w -u p peri o d.  
After scree ni n g ( Visit 1), all eli gi ble s u bjects will e nter i nt o a 4-wee k lea d -i n peri o d.  D uri n g t he lea d -i n 
peri o d, s u bjects will rec or d t heir dail y verti g o e x perie nce t o all o w f or a baseli ne assess me nt of t hese e ve nts.  
A n y da y wit h a rec or de d defi niti ve verti g o e pis o de, w hic h is a n e pis o de lasti n g at least 2 0 mi n utes 
(c orres p o n di n g t o a Verti g o Se verit y Sc ore of 2 or m ore), will be defi ne d as a defi niti ve verti g o da y ( D V D).  
F oll o wi n g t he lea d -i n peri o d, eli gi ble s u bjects will be ra n d o mize d t o [ADDRESS_422596] b o usi n g a 1: [ADDRESS_422597] u d y ( Wee k 1 2 ) or u p o n earl y disc o nti n uati o n  fr o m t he st u d y. 
N u m ber of S u bject s: 
T he pla n ne d sa m ple size f or t his st u d y is 1 4 2  s u bjects ([ADDRESS_422598] b o).  
Di a g n osis a n d M ai n Criteri a f or I ncl usi o n:  
S u bjects e nr olle d i n t he st u d y will ha ve u nilateral Me niere’s disease as o utli ne d b y t he  A merica n Aca de m y of 
Ot olar y n g ol o g y - Hea d a n d Nec k S ur ger y ( A A O -H N S) C o m mittee o n Heari n g a n d E q uili bri u m i n 1 9 9 5 
(C o m mittee o n Heari n g a n d E q uili bri u m, 1 9 9 5 ). 
T o be eli gi ble f or t his st u d y, eac h of t he f oll o wi n g criteria m ust be satisfie d wit h a “ Y E S” a ns wer ( u nless n ot 
a p plica ble):  
1. S u bject is a male or fe male a ge d [ADDRESS_422599] has a dia g n osis of defi nite u nilateral Me niere’s disease b y 1 9 9 5  A A O -H N S criteria.
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 1 8   N A M E O F S P O N S O R/ C O M P A N Y : 
 Ot o n o m y, I nc.   
N A M E O F FI NI S H E D P R O D U C T : 
 
N A M E O F A C TI V E I N G R E DI E N T( S) :                
 O T O- [ADDRESS_422600] 1 2 
m o nt hs acc or di n g t o 1 9 9 5  A A O -H N S criteria defi ne d as o ne of t he f oll o wi n g:   
a. T he arit h metic mea n of heari n g t hres h ol ds ( p ure t o ne a vera ge, P T A) at [ADDRESS_422601]’s heari n g l oss meets reas o na ble 
a u di o metric criteria f or heari n g l oss c haracteristic of Me niere’s disease, a n d if  so, it m ust  be 
j ustifie d a n d d oc u me nte d , a n d disc usse d wit h  t he me dical m o nit or. 
5.  If ta ki n g me dicati o n  f or Me niere’s disease (e. g., di uretics, vesti b ular s u p pressa nts, beta histi ne, 
a nti de pressa nts, or a n xi ol ytics), s u bject m ust be o n sta ble d oses of t he me dicati o n  f or at least [ADDRESS_422602] u d y.    
6.  Fe male s u bjects of c hil d beari n g p ote ntial [i.e., n ot s ur gicall y sterile a n d/ or n ot p ost-me n o pa usal 
( ≥ [ADDRESS_422603] me nstr ual peri o d a n d 4 5 years of a ge or ol der) ] m ust ha ve a ne gati ve uri n e 
pre g na nc y test bef ore e nr oll me nt.  W o me n of c hil d beari n g p ote ntial w h o are n ot a bsti ne nt fr o m se x 
wit h male part ners ma y be e ntere d i nt o t he st u d y if t he y are usi n g a n d willi n g t o c o nti n ue t o use 
hi g hl y effecti ve or “ d o u ble barrier” c o ntrace pti ve preca ut i o ns f or t he d urati o n of t he st u d y (e. g., oral 
c o ntrace pti ves, c o ntrace pti ve i m pla nt or i njecti o n, i ntra uteri ne de vice, or “ d o u ble barrier” met h o ds 
i ncl u di n g c o n d o m wit h dia p hra g m, male c o n d o m wit h cer vical ca p, male c o n d o m wit h s per mici de, or dia p hra g m a n d s per mici de).   
7.  S u bject is willi n g t o c o m pl y wit h t he pr ot oc ol a n d atte n d all st u d y visits.  
8.  S u bject is a ble t o use t he tele p h o ne  t o c o m plete t heir dail y diar y. 
9.  S u bject is a ble t o pr o vi de writte n i nf or me d c o nse nt, i ncl u di n g a gree me nt t o pri vac y la n g ua ge 
c o m plia nt wit h c o u ntr y a n d/ or l ocal re q uire me nts, bef ore t he i nitiati o n of a n y st u d y -relate d 
pr oce d ures.  
At t he c o m pleti o n of t he first 2 8 da ys of t he lea d -i n perio d:  
[ADDRESS_422604] 2 2 of 2 8 diar y e ntries d uri n g t he 4-wee k lea d -i n peri o d. 
 
Di a g n osis a n d M ai n Criteri a f or E xcl usi o n : 
T o be eli gi ble f or t his st u d y, eac h of t he f oll o wi n g criteria m ust be satisfie d wit h a “ N O” a ns wer: ( u nless n ot 
a p plica ble):  
1.  S u bject has a n i nfecti o n i n t he ear, si n uses, or u p per res pi[INVESTIGATOR_1305] y s yste m  at t he ti me of ra n d o mizati o n . 
2.  S u bject is pre g na nt or lactati n g.  
3.  S u bject has a hist or y of i m m u n o deficie nc y disease.  
4.  S u bject has acti ve or rece nt ( < 1 m o nt h pri or t o scree ni n g) mi d dle ear disease, i ncl u di n g b ut n ot 
li mite d t o:  c hr o nic otitis me dia, ac ute otitis me dia, mi d dle ear eff usi o ns, mi d dle ear atelectasis, or c h olesteat o ma.  
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 1 9   N A M E O F S P O N S O R/ C O M P A N Y : 
 Ot o n o m y, I nc.   
N A M E O F FI NI S H E D P R O D U C T : 
 
N A M E O F A C TI V E I N G R E DI E N T( S) :                
 O T O- [ADDRESS_422605] 1 of t he 4 f oll o wi n g mi grai ne o us feat u res: u nilateral 
hea dac he, p ulsati n g  q ualit y , ph ot o p h o bia , a n d vis ual a ura. 
[ADDRESS_422606] or y t hat, i n t he 
In vesti gat or’s or t he me dical m o nit or’s o pi [INVESTIGATOR_9384] o n, w o ul d pr o hi bit t he s u bject fr o m partici pati n g i n t he st u d y at scree ni n g or at t he ti me of ra n d o mizati o n . 
[ADDRESS_422607] or y of seri o us s u bsta nce a b use (e. g. c ocai ne, her oi n) wit hi n t he prece di n g [ADDRESS_422608], D ose a n d M o de of A d mi nistr ati o n:  
1 2  m g O T O -1 0 4 , si n gle 0. 2 m L i ntrat y m pa nic i njecti o n t o t he affecte d ear
 
D ur ati o n of Tre at me nt:    
Si n gle 0. 2 m L i ntrat y m pa nic i njecti o n t o t he affecte d ear  
Refere nce T her a p y, D ose a n d M o de of A d mi nistr ati o n:  
1 6 % p ol o xa mer s ol uti o n ( place b o), si n gle 0. 2 m L i ntrat y m pa nic i njecti o n t o t he affecte d ear  
O utc o me Me as ures f or E v al u ati o n:  
Pri mar y Efficac y E n d p oi nt:  
T he pri mar y efficac y e n d p oi nt is t he 2 8 -da y a vera ge  defi niti ve verti g o da ys ( D V D) at Wee k 1 2 [t he 4-wee k  
( 2 8-da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2].  A D V D is defi ne d as a da y w here t he s u bject rec or de d at 
least o ne verti g o e pis o de lasti n g at least [ADDRESS_422609] e pis o de e x perie nce d d uri n g t he da y.  
Sec o n dar y Efficac y E n d p oi nt s: 
•  S e verit y of verti g o e pis o des as meas ure d b y t he M ea n Se verit y Verti g o Sc ore  ( M S V S) at Wee k 1 2 
[t he 4-wee k  ( 2 8-da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2] 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 2 0   N A M E O F S P O N S O R/ C O M P A N Y : 
 Ot o n o m y, I nc.   
N A M E O F FI NI S H E D P R O D U C T : 
 
N A M E O F A C TI V E I N G R E DI E N T( S) :                
 O T O- 1 0 4  
 
De xa met has o ne   
•  T he t he 2 8-da y a vera ge  of n u m ber of da ys Sic k at h o me or  Be dri d de n  as a c o nse q ue nce of verti g o at 
Wee k 1 2 [ t he 4-wee k  ( 2 8-da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2] 
•  T he c ha n ge fr o m  baseli ne i n verti g o fre q ue nc y ( V F) at Wee k 1 2 [ t he 4-wee k  ( 2 8-da y) i nter val fr o m 
Wee k 9 t hr o u g h Wee k 1 2 ], w here verti g o fre q ue nc y is defi ne d as t he n u m ber of D V Ds rec or de d  
d uri n g t he 4 -wee k i nter val di vi de d b y t he n u m ber of n o n -missi n g diar y e ntr ies f or the rele va nt 
i nter val 
•  A vera ge  dail y c o u nt of verti g o e pis o des at Wee k 1 2 [ t he 4-wee k  ( 2 8-da y) i nter val fr o m Wee k 9 
t hr o u g h Wee k 1 2] 
E x pl orat or y Efficac y E n d p oi nts:  
•  T he c ha n ge  fr o m baseli ne i n verti g o fre q ue nc y ( V F) at W ee k 8, w here verti g o fre q ue nc y is defi ne d as 
t he n u m ber  of D V Ds  rec or de d d uri n g t he 4 -wee k i nter val di vi de d b y t he n u m ber of n o n -missi n g diar y 
e ntries f or t he rele va nt i nter val  
•  S e verit y of verti g o e pis o des as meas ure d b y t he  Mea n Se verit y Verti g o Sc ore  ( M S V S)  at W ee k 8   
•  A vera ge dail y c o u nt of verti g o e pis o des  at Wee k 8  
•  T he [ADDRESS_422610] u d y i nter val ( i.e., at Wee k 4, Wee k 8 a n d Wee k 1 2)  
•  T he n u m ber of 2 8 -da y a vera ge defi niti ve verti g o da ys ( D V D) d uri n g eac h 4-wee k st u d y i nter val 
( Wee k 1 t hr o u g h Wee k 4) a n d ( Wee k 5 t hr o u g h W ee k 8) 
•  Patie nt Gl o bal I m pressi o n of C ha n ge ( P GI C) at Wee ks 8 a n d 1 2  
•  S F -3 6 S ocial F u ncti o ni n g S u bscale  assess me nt at Wee ks 8 a n d 1 2  
•  Occ urre nce of N or mal acti vit y, Sli g ht li mitati o n, M o derate li mitati o n, Sic k at h o me, a n d Be dri d de n 
e ve nts as a c o nse q ue nce of verti g o at Wee k 4, Wee k 8, a n d Wee k 1 2  
Safet y Assess me nts : 
S afet y assess me nts  i ncl u de: 
•  A d verse e ve nts  •  A u di o metr y assess me nts  
•  T y m pa n o metr y  
•  O t osc o pic e xa mi nati o ns 
•  Cli nical la b ora t or y meas ure me nts 
•  Vital si g n meas ure me nts  
•  C ol u m bia -S uici de Se verit y Rati n g Scale ( C -S S R S): Baseli ne a n d Si nce Last Visit versi o ns  
St atistic al Met h o ds:  
T he pri mar y efficac y e n d p oi nt is t he  2 8 -da y a vera ge  D V D at Wee k 1 2 [t he 4-wee k ( 2 8-da y) i nter val fr o m 
Wee k 9 t hr o u g h Wee k 1 2 ].   T he tar get t otal sa m ple size f or t he st u d y is 1 4 2 ra n d o mize d wit h 1: 1 all ocati o n, 
7 1 i n eac h treat me nt gr o u p 
T he pri mar y a nal ysis will be c o n d ucte d usi n g a Ne gati ve Bi n o mial m o del at Wee k 1 2.  F or t he Ne gati ve 
Bi n o mial a nal y sis, a sa m ple size of 1 4 2 s u bjects will pr o vi de a p pr o xi matel y 9 0 % p o wer t o detect a differe nce 
bet wee n gr o u ps i n t he [ADDRESS_422611] b o, res pecti vel y, f or a n esti mate d  rati o of 0. 5 3. It is als o ass u me d t hat t he distri b uti o n 
s ha pe para meter is 1. 0 4.  T he ass u m pti o ns use d f or t he Ne gati ve Bi n o mial m o del were base d o n t he pre vi o usl y 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 2 1   N A M E O F S P O N S O R/ C O M P A N Y : 
 Ot o n o m y, I nc.   
N A M E O F FI NI S H E D P R O D U C T : 
 
N A M E O F A C TI V E I N G R E DI E N T( S) :                
 O T O- [ADDRESS_422612] u d y 1 0 4 -2 0 1 5 0 8 ( data o n file). T he calc ulati o ns were c o n d ucte d usi n g E A S T v 6. [ADDRESS_422613] u d y is t he f ull a nal ysis set ( F A S).  T he F A S  will i ncl u de all s u bjects 
w h o are ra n d o mize d, recei ve st u d y dr u g, ha ve a baseli ne D V D meas ure me nt f or t he [ADDRESS_422614] o ne da y of D V D meas ure me nt at Wee k 1 2 [t he 4 -wee k ( 2 8 da y) i nter val fr o m Wee k 9 t hr o u g h 
Wee k 1 2 ].    
I n t he pri mar y efficac y a nal ysis if a s u bject is missi n g t heir Wee k [ADDRESS_422615] of missi n g dail y diar y ( D D) data o n t he res ults of t he 
pri mar y e n d p oi nt a nal ysis f or t he F A S a n d f or s u bjects w h o m disc o nti n ue d t he st u d y pri or  t o e nteri n g t he 
Wee k 1 2 i nter val . w hic h i ncl u de vari o us i m p utati o n met h o ds as s pecifie d i n t he Statistical A nal ysis Pla n 
(S A P).  S u bjects will be i ncl u de d i n t he treat me nt gr o u p t o w hic h t he y were ra n d o mize d re gar dless of t he 
act ual st u d y dr u g recei ve d.
  
If t he pri mar y e n d p oi nt c o m paris o n bet wee n t he t w o treat me nt gr o u ps is statisticall y si g nifica nt i n fa v or of 
O T O- 1 0 4 t he n a cl ose d testi n g, gate -kee pi n g pr oce d ure, will be use d t o c o m pare t he f oll o wi n g sec o n dar y efficac y e n d p oi nts se q ue ntiall y :  
1.  S e verit y of verti g o e pis o des as meas ure d b y t he M ea n Verti g o Se verit y Sc ore  ( M S V S) at Wee k 
1 2 [ t he 4-wee k  ( 2 8-da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2] 
2.  T he 2 8 -da y a vera ge  of n u m ber of da ys Sic k at h o me or  Be dri d de n  as a c o nse q ue nce of verti g o at 
Wee k 1 2 [ the 4 -wee k  ( 2 8-da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2] 
3.  Perce nt of s u bjects ac hie vi n g a 7 5 % re d ucti o n fr o m baseli ne i n 2 8 -da y a vera ge  D V D at Wee k 1 2  
4.  Perce nt of s u bjects ac hie vi n g a 1 0 0 % re d ucti o n fr o m baseli ne (i.e., c o u nt of zer o)  i n [ADDRESS_422616] ke y sec o n dar y e n d p oi nt t hat d oes n ot de m o nstrate a statisticall y si g nifica nt differe nce bet wee n 
gr o u ps i n fa v or of O T O -1 0 4, t he gate -kee pi n g pr oce d ure e n ds a n d a n y s u bse q ue nt ke y sec o n dar y e n d p oi nt p -val ues will be c o nsi dere d as a n o mi nal p val ue(s).  
T he gate -kee pi n g pr oce d ure c o ntr ols t he T y pe I err or f or t he f o ur pla n ne d c o m paris o ns a n d, t heref ore, t here 
will be n o α s pe n di n g pe nalt y ass ociate d wit h t he pla n ne d ke y sec o n dar y c o m paris o ns.  
T he re mai ni n g sec o n dar y e n d p oi nts c o m paris o n will n ot g o t hr o u g h t he gate kee pi n g pr oce d ure a n d t heref ore 
t he re p orte d p-val ues will be re p orte d as n o mi nal p -val ues.    All efficac y h y p ot h esis tests will be 2 -si de d a n d 
perf or me d at α = 0. 0 5 si g nifica nce le vel  u nless ot her wise s pecifie d i n t he S A P.   
Ti me a n d E ve nts Sc he d ule:  See  
Ta ble  1 . 
 
 
 
  
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 2 2   T a ble  1: Ti me a n d E ve nts Sc he d ule  
Pr oce d ure  Scree ni n g  Le a d -I n B aseli ne1/ 
Tre at me nt 
Visit  F oll o w -u p 
Visit  F oll o w -u p 
Visit  E n d -of -St u d y/  
E arl y 
Ter mi n ati o n  U nsc he d ule d 
Visit  
Visit 1  –  Visit 2  Visit 3  Visit 4  Visit 52 U nsc he d ule d  
–  –  –  Wee k 4  Wee k 8  Wee k 1 2  N/ A  
U p t o [ADDRESS_422617] art 
of le a d -i n D a y -2 8 t o -1 
( + 3 d a ys) D a y 1  D a y 2 8  
( ± 2 d a ys)  D a y 5 6  
( ± 2 d a ys)  D a y 8 4  
(+ 4  d a ys)  N/ A  
I nf or me d c o nse nt (i ncl u di n g 
pri vac y la n g ua ge/ d oc u me nts)  X       
Eli gi bilit y criteria  X X3 X     
Me dical hist or y4 X  X     
C o nc o mita nt me dicati o ns  X  X X X X X 
Vital si g n meas ure me nts5 X  X X X X X 
Hei g ht a n d wei g ht meas ure me nts  X     X6  
Pre g na nc y test7 X  X   X  
Cli nical la b orat or y test8 X  X   X X as i n dicate d  
T y m pa n o metr y  X  X X X X X as i n dicate d  
A u di o metr y  X  X X X X X as i n dicate d  
Ot osc o p y X  X X X X X 
P GI C      X X  
S F -[ADDRESS_422618] o n I V R S diar y 
use a n d re vie w a n y c o m plia nce 
iss ues1 0     X  X X X   
Ra n d o mizati o n1 1 ,1 2   X     
 
 
 
  
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 2 3   Pr oce d ure  Scree ni n g  Le a d -I n B aseli ne1/ 
Tre at me nt 
Visit  F oll o w -u p 
Visit  F oll o w -u p 
Visit  E n d -of -St u d y/  
E arl y 
Ter mi n ati o n  U nsc he d ule d 
Visit  
Visit 1  –  Visit 2  Visit 3  Visit 4  Visit 52 U nsc he d ule d  
–  –  –  Wee k 4  Wee k 8  Wee k 1 2  N/ A  
U p t o [ADDRESS_422619] art 
of le a d -i n D a y -2 8 t o -1 
( + 3 d a ys) D a y 1  D a y 2 8  
( ± 2 d a ys)  D a y 5 6  
( ± 2 d a ys)  D a y 8 4  
(+ 4  d a ys)  N/ A  
A d mi nister st u d y dr u g   X      
A d verse e ve nt m o nit ori n g    X X X X X 
[ADDRESS_422620] u g . Re vie w eli gi bilit y criteria at t he baseli ne visit t o e ns ure s u bjects re mai n 
eli gi ble f oll o wi n g t he lea d -i n peri o d. 
2 Pr oce d ures sc he d ule d f or Visit 5 will be perf or me d at t he e n d of t he f oll o w - up peri o d ( + 4 da ys) or u p o n earl y disc o nti n uati o n fr o m t he st u d y.   If Visit [ADDRESS_422621] has met t he i ncl usi o n/e xcl usi o n criteria as a p pr o priate at scree ni n g, t he s u bject will e nter a [ADDRESS_422622] res ults  are a vaila ble . 
9 C ol u m bia -S uici de Se verit y Rati n g Scale: T he Baseli ne versi o n will be use d at t he Scree ni n g visit a n d t he Si nce Last Visit versi o n wil l be use d at all s u bse q ue nt 
visits.  
[ADDRESS_422623] has met all prere q uisites f or ra n d o mizati o n a n d has c o m plete d all sc he d ule d p r oce d ures f or Da y 1. 
1 2 S u bjects will be ra n d o mize d usi n g la b orat or y res ults fr o m Visit 1; la b orat or y res ults fr o m Visit 2 are n ot re q uire d f or ra n d o mizati o n.  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422624] u dies wit h 
O T O -1 0 4 i n Me niere’s disease: a n e x pl orat or y P hase [ADDRESS_422625] u d y de m o nstrate d t hat a si n gle i ntrat y m pa nic i njecti o n of O T O- 1 0 4 at d oses of 3 m g or 1 2 m g was  
safe a n d well t olerate d i n s u bjects wit h Me niere’s disease.  I n a d diti o n, t he tre n ds i n t he data 
s u g gest treat me nt wit h [ADDRESS_422626] u d y t heref ore ra n d o mize d 1 5 4 s u bjects wit h u nilateral Me niere’s disease t o treat me nt 
wit h [ADDRESS_422627] b o res p o nse i n all ot her O T O-1 0 4 cli nical trials i n Me niere’s 
disease patie nts.  T he p ur p ose of t he c urre nt P hase 3 st u d y, 1 0 4- 2 0 1 8 1 1, t heref ore, is t o f urt her i n vesti gate t he efficac y of O T O - 1 0 4 i n s u bjects wit h Me niere’s disease, i nf or me d b y t he res ults 
of st u dies 1 0 4- 2 0 1 5 0 6 a n d 1 0 4- 2 0 1 5 0 8.   
2.  O B J E C TI V E S  
2. 1.  Pri m ar y O bjecti ve  
T he pri mar y o bjecti ve is t o  i n vesti gate t he efficac y of O T O- 1 0 4 i n s u bjects wit h Me niere’s 
disease, as meas ure d b y t he n u m ber of defi niti ve verti g o da ys ( D V D) at Wee k 1 2 (t he 4 -wee k i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2). 
2. 2.  Sec o n d ar y O bjecti ve  
T he sec o n dar y o bjecti ve is t o  i n vesti gate t he safet y pr ofile of O T O- 1 0 4 i n s u bjects wit h Me niere’s disease.  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422628] b o usi n g a 1: [ADDRESS_422629] will be a p pr o xi matel y 1 6 wee ks, i ncl u di n g a 4- wee k 
lea d-i n peri o d bef ore d osi n g (a si n gle i njecti o n), f oll o we d b y a 1 2- wee k f oll o w- u p peri o d. 
After scree ni n g ( Visit 1), all eli gi ble s u bjects will e nter i nt o a [ADDRESS_422630] 2 0 mi n utes (c orres p o n di n g t o a Verti g o Se verit y Sc ore of 2 or m ore), will be 
defi ne d as a defi niti ve verti g o da y ( D V D).  F oll o wi n g t he lea d -i n peri o d, eli gi ble s u bjects will be ra n d o mize d t o [ADDRESS_422631] b o usi n g a 1: [ADDRESS_422632] u d y site at Wee ks 4 a n d 8 f or a d diti o nal efficac y a n d/ or safet y assess me nts. Efficac y a n d 
safet y assess me nts will als o be c o m plete d at t he e n d of st u d y ( Wee k 1 2) or u p o n earl y 
disc o nti n uati o n fr o m t he st u d y. 
4.  S T U D Y P O P U L A TI O N  
4. 1.  Ge ner al C o nsi der ati o ns  
A p pr o xi matel y [ADDRESS_422633] u d y will ha ve u nilateral Me niere’s disease as o utli ne d b y t he A merica n Aca de m y of Ot olar y n g ol o g y - Hea d a n d Nec k S ur ger y ( A A O- H N S) C o m mittee o n Heari n g a n d 
E q uili bri u m i n 1 9 9 5 (C o m mittee o n Heari n g a n d E q uili b ri u m, 1 9 9 5). 
T o be eli gi ble f or t his st u d y, eac h of t he f oll o wi n g criteria m ust be  satisfie d wit h a “ Y E S” a ns wer 
( u nless n ot a p plica ble): 
1.  S u bject is a male or fe male a ge d [ADDRESS_422634] has a dia g n osis of defi nite u nilateral Me niere's disease b y [ADDRESS_422635] 1 2 m o nt hs acc or di n g t o 1 9 9 5 A A O -H N S criteria defi ne d as o ne of t he f oll o wi n g:  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 2 7   
 a. T he arit h metic mea n of h eari n g t hres h ol ds ( p ure t o ne a vera ge, P T A) at [ADDRESS_422636] 's heari n g l oss meets reas o na ble 
a u di o metric criteria f or heari n g l oss c haracteristic of Me niere's disease, a n d if s o, it 
m ust be j ustifie d a n d d oc u me nte d,  a n d disc usse d wit h  t he me dical m o nit or. 
5.  If ta ki n g me dicati o n f or Me niere’s disease (e. g. , di uretics, vesti b ular s u p pressa nts, 
beta histi ne, a nti de pressa nts, or a n xi ol ytics), s u bject m ust be o n s ta ble d oses of t he 
me dicati o n  f or at least [ADDRESS_422637] u d y.   
6.  Fe male s u bjects of c hil d beari n g p ote ntial [i.e., n ot s ur gicall y sterile a n d/ or n ot p ost-
me n o pa usal ( ≥ [ADDRESS_422638] r ual peri o d a n d 4 5 years of a ge or ol der)] m ust ha ve a ne gati ve uri ne pre g na nc y test bef ore ra n d o mizati o n. W o me n of c hil d beari n g p ote ntial w h o are n ot a bsti ne nt fr o m se x wit h male part ners ma y be e ntere d i nt o t he st u d y 
if t he y are usi n g a n d willi n g t o c o nti n ue t o use hi g hl y effecti ve or “ d o u ble barrier” 
c o ntrace pti ve preca uti o ns f or t he d urati o n of t he st u d y (e. g., oral c o ntrace pti ves, c o ntrace pti ve i m pla nt or i njecti o n, i ntra uteri ne de vice, “ d o u ble barrier” met h o ds 
i ncl u di n g male c o n d o m wit h dia p hra g m, mal e c o n d o m wit h cer vical ca p, male c o n d o m 
wit h  s per mici de, or dia p hra g m a n d s per mici de).  
7.  S u bject is willi n g t o c o m pl y wit h t he pr ot oc ol a n d atte n d all st u d y visits.  
8.  S u bject is a ble t o use t he tele p h o ne  t o c o m plete t heir dail y diar y . 
9.  S u bject is a ble t o pr o vi de writte n i nf or me d c o nse nt, i ncl u di n g a gree me nt t o pri vac y 
la n g ua ge c o m plia nt wit h c o u ntr y a n d/ or l ocal re q uire me nts, bef ore t he i nitiati o n of a n y 
st u d y-relate d pr oce d ures. 
At t he c o m pleti o n of t he first 2 8 da ys of t he lea d-i n peri o d: 
[ADDRESS_422639] be satisfie d wit h a “ N O” a ns wer: 
( u nless n ot a p plica ble): 
1.  S u bject has a n i nfecti o n i n t he ear, si n uses, or u p per res pi[INVESTIGATOR_1305] y s yste m at t he ti me of 
ra n d o mizati o n. 
2.  S u bject is pre g na nt or lactati n g.  
3.  S u bject has a hist or y of i m m u n o deficie nc y disease.  
4.  S u bject has acti ve or rece nt ( < 1 m o nt h pri or t o scree ni n g) mi d dle ear disease, i ncl u di n g 
b ut n ot li mite d t o:  c hr o nic otitis me dia, ac ute otitis me dia, mi d dle ear eff usi o ns, mi d dle 
ear atelectasis, or c h olesteat o ma.  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422640] 1 
of t he 4 f oll o wi n g mi grai ne o us featires: u nilateral hea dac he, p ulsati n g q ualit y, p h ot o p h o bia, a n d vis ual a ura. 
[ADDRESS_422641] or y  
t hat, i n t he I n vesti gat or’s or t he me dical m o nit or’s o pi [INVESTIGATOR_9384] o n, w o ul d pr o hi bit t he s u bject 
fr o m partici pati n g i n t he st u d y at scree ni n g or at t he ti me of ra n d o mizati o n . 
[ADDRESS_422642] or y of seri o us s u bsta nce a b use (e. g. c ocai ne, her oi n) wit hi n t he 
prece di n g [ADDRESS_422643] u d y  of O T O - 1 0 4. 
5.  R A N D O MI Z A TI O N A N D B LI N DI N G  
5. 1.  O ver vie w  
At t he c o ncl usi o n of t he scree ni n g/lea d- i n peri o d, eli gi ble s u bjects will be ra n d o ml y assi g ne d t o 
eit her O T O- [ADDRESS_422644] b o i n a 1: 1 all ocati o n rati o , base d o n a c o m p uter- ge nerate d 
ra n d o mizati o n sc he d ule.   
•  1 2 m g O T O- 1 0 4; si n gle, i ntrat y m pa nic i njecti o n  
•  Place b o; si n gle, i ntrat y m pa nic i njecti o n  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422645] has met all 
prere q uisites f or ra n d o mizati o n a n d has c o m plete d all sc he d ule d pr oce d ures f or Da y 1 ( Visit 2).   St u d y site pers o n nel, w h o are bli n de d t o treat me nt assi g n me nt, will recei ve a ra n d o mizati o n 
n otificati o n i n dicati n g t he kit n u m ber  ( pac ka ge d st u d y dr u g), a n d t he date a n d ti me of 
ra n d o mizati o n f or eac h s u bject.  O nce assi g ne d, kit n u m bers ca n n ot be re -assi g ne d.  S u bjects will be c o nsi dere d e nr olle d i nt o t he st u d y o nce t he y are ra n d o mize d a n d assi g ne d a u ni q ue 
ra n d o mizati o n n u m ber. 
St u d y sites will pr o vi de t he i nf or mati o n c o ntai ne d i n t he I W R S ra n d o mizati o n n otificati o n  t o t he 
u n bli n de d q ualifie d me dical pr ofessi o nal ( Q M P) res p o nsi ble f or pre parati o n of t he s yri n ge 
c o ntai ni n g st u d y dr u g.  T he u ni q ue kit n u m ber pr o vi de d b y t he I W R S will c orres p o n d t o a kit of 
pac ka ge d st u d y dr u g la bele d wit h t he i de ntical kit n u m ber.  T he Q M P  will pre pare t he s yri n ge fr o m t he c o nte nts of t he st u d y dr u g pac ka ge c orres p o n di n g t o t he I W R S kit n u m ber acc or di n g t o 
t he i nstr ucti o ns i n t he st u d y P har mac y Ma n ual.   T he s u bject i de ntificati o n n u m ber a n d kit 
n u m ber m ust b ot h be rec or de d i n t he s u bject’s rec or d at t he Baseli ne visit . 
5. 2. 3.  R a n d o miz ati o n Al g orit h m 
S u bjects will be ra n d o mize d i n a 1: [ADDRESS_422646]’s ra n d o mizati o n n u m ber will deter mi ne t he ra n d o mize d treat me nt assi g n me nt.  N u m bere d kits will 
be dis pe nse d b y t he Q M P  base d o n t he treat me nt assi g n me nt.  St u d y dr u g kits will be la bele d 
wit h a u ni q ue kit n u m ber usi n g a se parate a n d i n de pe n de nt ra n d o mizati o n al g orit h m. 
5. 3.  Bli n di n g  
T he st u d y will be d o u ble- bli n de d.  T o mai ntai n t he bli n d f or site pers o n nel i n v ol ve d i n st u d y assess me nts, bli n di n g pr oce d ures m ust be f oll o we d acc or di n g t o t he Site Bli n di n g Pla n a n d briefl y descri be d bel o w: 
Treat me nt s yri n ges will be pre -l oa de d b y a n u n bli n de d Q M P .  Eac h s yri n ge will be pre pare d 
acc or di n g t o t he detaile d i nstr ucti o ns i n t he P har mac y Ma n ual i n a ma n ner t hat pre ve nts vis ualizati o n of s yri n ge c o nte nts b y all ot her st u d y staff t hr o u g h t he use of a s yri n ge o verla bel.  
I n a d diti o n, a n y i nteracti o n wit h s u bjects wit h re gar d t o t he c ollecti o n, re vie w or disc ussi o n of 
st u d y assess me nts, wit h t he e xce pti o n of ot osc o pic e xa ms, will be d o ne b y t he st u d y c o or di nat or, a u di ol o gist or s o me o ne ot her t ha n t he Q M P  w h o pre pare d t he s yri n ge a n d t he p h ysicia n w h o 
a d mi nistere d t he i ntrat y m pa nic i njecti o n of st u d y dr u g.  E ver y eff ort s h o ul d be ma de t o e ns ure 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422647]’s treat me nt all ocati o n w o ul d facilitate 
s pecific e mer ge nc y treat me nt.  T he p h ysicia n w h o a d mi nistere d t he st u d y dr u g is u n bli n d e d at 
t he ti me of i njecti o n.  If t he p h ysicia n w h o a d mi nistere d t he st u d y dr u g is n ot a vaila ble or d oes n ot rec ollect t he treat me nt a d mi nistere d, t he I n vesti gat or ca n access t he u n bli n de d dr u g 
acc o u nta bilit y rec or ds c o m plete d a n d retai ne d b y t he Q M P w he n pre pari n g O T O- [ADDRESS_422648] b o.  
I n vesti gat ors ma y  als o u n bli n d via t he I nteracti ve Res p o nse Tec h n ol o g y (I R T) ra n d o mizati o n s yste m f or t he st u d y, w hic h per mits ra pi d u n bli n di n g.  I n all cases, t he In vesti gat or m us t c o ntact 
t he me dical m o nit or as s o o n as is pr actical after u n bli n di n g has occ urre d a n d e mer ge nc y 
treat me nt i nitiate d. 
If t he bli n d is br o ke n, t he s u bject will c o nti n ue t o be f oll o we d a n d e val uate d per- pr ot oc ol.  T he 
date, ti me, a n d reas o n f or t he u n bli n di n g m ust be d oc u me nte d o n t he a p pr o priate pa ge of t he 
e C R F.  
T he ra n d o mizati o n sc he d ule or bl oc ki n g fact or(s) will n ot b e re veale d t o st u d y s u bjects, 
In vesti gat ors, cli nical staff, site ma na gers or S p o ns or re prese ntati ves u ntil all s u bjects ha ve 
c o m plete d t he trial a n d t he data base has bee n fi nalize d b y t he S p o ns or. 
6.  D O S A G E A N D A D MI NI S T R A TI O N  
6. 1.  St u d y Dr u g A d mi nistr ati o n  
O T O - [ADDRESS_422649] u d y pers o n nel.  O T O -1 0 4 1 2 m g will be a d mi nistere d  as a 
si n gle, 0. 2 m L i ntrat y m pa nic i njecti o n of 6 0 m g/ m L O T O- [ADDRESS_422650] b o gels pri or t o a d mi nistrati o n, it ca n be c o ole d t o a li q ui d b y eit her placi n g t he 
s yri n ge o n a n ice pac k c o vere d b y a sterile dra pe or i n t he refri gerat or f or se veral mi n utes.    
T he rec o m me n de d i njecti o n pr oce d ure f or i ntrat y m pa nic a d mi nistrati o n of O T O- 1 0 4 i n 
Me niere’s disease s u bjects is as f oll o ws .  A ve ntilati o n h ole i n t he t y m pa nic me m bra ne is n ot 
nee de d  d ue t o t he s mall i njecti o n v ol u me.     
1.  Place t he s u bject i n a rec u m be nt p ositi o n wit h t he st u d y dr u g ear u p war ds.   
2.  Pri or t o a d mi nistrati o n, c o nfir m t he ear t o be treate d is t he affecte d st u d y dr u g ear.  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422651] hetic  (e. g.    or li d ocai ne s pra y) u ntil t he t y m pa nic me m bra ne is 
n u m b.  If a p plica ble, s ucti o n a wa y t he t o pi[INVESTIGATOR_2855] l i d ocai ne or li d ocai ne/ pril ocai ne crea m.  P he n ol s h o ul d n ot be use d t o a nest hetize t he t y m pa nic me m bra ne.  
4.  Usi n g t he pre pare d s yri n ge, i nsert t he nee dle i nt o t he i nferi or - p osteri or q ua dra nt of t he 
t y m pa nic me m bra ne at t he le vel of t he r o u n d wi n d o w, ta ki n g care n ot t o i nsert t he nee dle f urt her t ha n necessar y.   
5.  Wit h t he nee dle be vel faci n g i n t he i nferi or - p osteri or directi o n, i nject 0. [ADDRESS_422652]’s e C R F.  T his will i ncl u de all s y m pt o matic relief me dicati o ns f or Me niere’s disease s ym pt o ms, prescri pti o n dr u gs, her bal pr o d ucts, vita mi ns, mi nerals, a n d o ver-t he-c o u nter me dicati o ns ta ke n wit hi n 3 0 da ys bef ore 
Scree ni n g , w hic h will be c o nsi dere d pri or t hera p y.  O nl y sta ble d oses (at least [ADDRESS_422653] u d y) of me dicati o ns f or Me niere’s disease s y m pt o ms (e. g. di uretics, vesti b ular s u p pressa nts, beta histi ne, a nti de pressa nts, or a n xi ol ytics) are 
all o we d.  A n y c o nc o mita nt me dicati o n dee me d necessar y f or t he welfare of t he s u bject d uri n g 
t he st u d y ma y be gi ve n at t he discreti o n of t he I n vesti gat or e xce pt f or t h ose liste d i n Secti o n  7. 1.  T he me dical m o nit or s h o ul d be alerte d t o a n y c ha n ges i n c o nc o mita nt me dicati o ns.  A n y c ha n ges 
i n c o nc o mita nt me dicati o ns will be rec or de d i n t he s u bject’s e C R F. 
7. 1.  Pr o hi bite d T her a p y D uri n g t he St u d y Peri o d  
T he f oll o wi n g t hera pi[INVESTIGATOR_66491] o hi bite d d uri n g t he st u d y: 
•  S yste mic c ortic oster oi ds  
•  I m m u n os u p pressi ve me dicati o ns •  I ntrat y m pa nic i njecti o n ot her t ha n t hat o utli ne d i n t he c urre nt st u d y 
•  S ur ger y f or treat me nt of Me niere’s disease  
•  Ot her i n vesti gati o nal dr u g(s) or de vice(s)  
Use of a n y of t hese pr o hi bite d t hera pi[INVESTIGATOR_8775] c o nsi dere d a pr ot oc ol de viati o n. 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 3 2   
 7. 2.  S y m pt o m atic Relief Me dic ati o ns  
It is rec o g nize d t hat s u bjects ma y at ti mes use certai n me dicati o ns f or relief of s y m pt o ms relate d 
t o Me niere’s disease d uri n g t he c o urse of t he st u d y.  Use of vesti b ular s u p pressa nts a n d a nti-
e metics is all o we d as s y m pt o matic relief me dicati o ns.  Me dicati o ns ta ke n f or t he ac ute treat me nt of a verti g o attac k m ust be rec or de d as s uc h i n t he e C R F.  T he use of i ntrat y mpa nic ster oi ds, 
i ntrat y m pa nic ge nta mici n, or ear s ur ger y at a n y ti me d uri n g t he st u d y will be c o nsi dere d a 
pr ot oc ol de viati o n.  A n y c ha n ges re p orte d b y t he s u bjects i n c o nc o mita nt me dicati o ns s h o ul d be rec or de d i n t he s u bject’s e C R F. 
8.  S T U D Y E V A L U A TI O N S  
8. 1.  St u d y Pr oce d ures b y Visit  
8. 1. 1.  Visit 1: U p t o 1 4 d a ys pri or t o i niti ati o n of le a d- i n peri o d ( Scree ni n g) 
Beca use a u di ol o g y, t y m pa n o metr y a n d ot osc o pic e xa ms are c o nsi dere d r o uti ne f or t his patie nt 
p o p ulati o n, data o btai ne d fr o m assess me nts perf or me d pri or t o d oc u me ntati o n of i nf or me d 
c o nse nt ca n be use d as scree ni n g data.  I n t hese cases, t he data s h o ul d ha ve bee n c ollecte d wit hi n 1 4 d a ys of i nitiati o n of t he lea d -i n peri o d. 
T he f oll o wi n g assess me nts will be perf or me d at Visit 1.  
•  I nf or me d c o nse nt 
•  C o nfir m eli gi bilit y criteria  
•  Me dical hist or y  
•  C o nc o m ita nt me dicati o ns •  Vital si g ns  
•  Hei g ht a n d wei g ht meas ure me nts  
•  Ser u m  pre g na nc y test (f or fe male s u bjects of c hil d beari n g p ote ntial o nl y)  •  Cli nical la b orat or y test  
•  T y m pa n o metr y 
•  A u di o metr y  •  Ot osc o p y 
•  C- S S R S assess me nt: Baseli ne versi o n  
•  Re vie w I V R S diar y i nstr uc ti o ns wit h s u bject 
8. 1. 2.  Le a d -I n Peri o d ( D a y - 2 8 t hr o u g h - 1 ( + 3 d a ys)) 
T he s u bject will rec or d t heir dail y verti g o e x perie nce d uri n g t he e ntire lea d-i n peri o d u ntil 
ra n d o mizati o n, i neli gi bilit y or wit h dra wal of c o nse nt.  T he deter mi nati o n of w het her s u bjects 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 3 3   
 mee t I ncl usi o n Criteria N o. 1 0 a n d 1 1 will be c o n d ucte d 2 8 da ys after i nitiati o n of t he lea d-i n 
peri o d. 
8. 1. 3.  Visit 2: D a y 1 ( B aseli ne/ D ose A d mi nistr ati o n)  
T he f oll o wi n g assess me nts will be perf or me d at Visit 2.  
•  C o nfir m eli gi bilit y criteria  
•  Me dical hist or y  
•  C o nc o mita nt me dicati o ns  
•  Vital si g ns  •  Uri ne pre g na nc y test (f or fe male s u bjects of c hil d beari n g p ote ntial o nl y)  
•  Cli nical la b orat or y test  
•  T y m pa n o metr y •  A u di o metr y 
•  Ot osc o p y 
•  S F - 3 6 S ocial F u ncti o ni n g S u bscale assess me nt •  C- S S R S assess me nt, Si nce Last Visit versi o n  
•  Ra n d o mize a n d a d mi nister O T O - [ADDRESS_422654] b o (all assess me nts i n t he a b o ve list 
m ust be c o n d ucte d pri or t o O T O- [ADDRESS_422655] b o a d mi nistrati o n)  
•  Re vie w s u bject I V R S diar y i nstr ucti o ns •  A d verse e ve nts (t o be c ollecte d d uri n g or after O T O - 1 0 4 a d mi nistrati o n) 
8. 1. 4.  Vis it 3, 4: Wee k 4 a n d 8 ( ± 2 d a ys) ( F oll o w U p) 
T he f oll o wi n g assess me nts will be perf or me d at Visit 3 a n d 4.  
•  C o nc o mita nt me dicati o ns  
•  Vital si g ns  
•  T y m pa n o metr y •  A u di o metr y  
•  Ot osc o p y 
•  Patie nt Gl o bal I m pressi o n of C ha n ge ( P GI C)  – Wee k 8 o nl y  •  S F - 3 6 S ocial F u ncti o ni n g S u bscale assess me nt – Wee k 8 o nl y 
•  C- S S R S assess me nt, Si nce Last Visit versi o n  
•  Re vie w s u bject I V R S diar y i nstr ucti o ns •  A d verse e ve nts  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 3 4   
 8. 1. 5.  Visit 5 : Wee k 1 2  ( + 4 d a ys) ( E n d of St u d y/ E arl y Ter mi n ati o n) 
If Visit [ADDRESS_422656] is a n earl y disc o nti n uati o n or wit h dre w c o nsent. 
T he  f oll o wi n g assess me nts will be perf or me d at Visit 5. 
•  C o nc o mita nt me dicati o ns  
•  Vital si g ns  
•  Uri ne pre g na nc y test (f or fe male s u bjects of c hil d beari n g p ote ntial o nl y)  
•  Cli nical la b orat or y test  
•  T y m pa n o metr y 
•  A u di o metr y 
•  Ot osc o p y 
•  P GI C  
•  S F - 3 6 S ocial F u ncti o ni n g S u bscale assess me nt  •  C- S S R S assess me nt, Si nce Last Visit versi o n  
•  A d verse e ve nts 
8. 2.  Effic ac y E v al u ati o ns  
Efficac y assess me nts i ncl u de:  
•  C haracterizati o n of Dail y Verti g o E x perie nce  
•  P GI C (e x pl orat or y e n d p oi nt)  •  S F -3 6 S ocial F u ncti o ni n g S u bscale assess m e nt (e x pl orat or y e n d p oi nt)  
T o mai ntai n t he d o u ble- bli n d of t he st u d y, it is re q uire d t hat a n y i nteracti o n wit h s u bjects i n t he 
c ollecti o n, re vie w, or disc ussi o n of t hese assess me nts be d o ne b y a trai ne d staff me m ber ot her t ha n t he In vesti gat or w h o a d mi nis tere d t he i ntrat y m pa nic i njecti o n of st u d y dr u g.  A n e xce pti o n 
ma y be ma de o nl y if it i n v ol ves t he safet y of t he s u bject.  
8. 2. 1.  D ail y Di ar y – Verti g o E x perie nce  
S u bjects will rec or d t heir dail y verti g o e x perie nce via a n I V R S dail y diar y b y rec or di n g t he 
se verit y of t he w orst verti g o e pis o de e x perie nce d  d uri n g t he da y, t he effect of verti g o o n t heir 
dail y acti vities, a n d t he n u m ber of verti g o e pis o des e x perie nce d d uri n g t he da y.  S u bjects eli gi ble 
at scree ni n g will be gi n usi n g t he I V R S dail y diar y at t he start of t he lea d-i n peri o d, a n d if ra n d o mize d, will c o nti n ue t o rec or d t heir dail y verti g o e x perie nce t hr o u g h o ut t he re mai n der of 
t he st u d y.  S u bjects will be a ble t o rec or d misse d diar y e ntries f or 1 da y after a misse d e ntr y.  
C o m plia nce wit h t he I V R S verti g o diar y will be m o nit ore d.   
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 3 5   
 Usi n g t he dail y verti g o scales  de vel o pe d b y Gates (Gates, 2 0 0 0 ; Gates, 2 0 0 4 ; Gates 2 0 0 5 ; Gates, 
2 0 0 6 ) a n d a da pte d t o a n I V R S, s u bjects are i nstr ucte d t o rec or d t he sc ore t hat best c orres p o n ds t o 
t he w orst verti g o e pis o de e x perie nce d eac h da y , a n d t he effect o n t heir dail y acti vities of t heir 
t otal verti g o e x perie nce t hat da y usi n g a 5- p oi nt sc ori n g s yste m: 
Verti g o Se verit y Sc ore  
0 = Verti g o -free da y 1 = Mil d - a n attac k lasti n g less t ha n 2 0 mi n utes  2 = M o derate - a n attac k lasti n g m ore t ha n 2 0 mi n utes 
3 = Se vere - a n attac k lasti n g m ore t ha n 2 0 mi n utes a n d acc o m pa nie d b y na usea a n d/ or 
v o miti n g 
4 = T he w orst attac k e x perie nce d t o date  
Effect of Verti g o  o n Acti vit y Le vel 
0 = N or mal Acti vit y  1 = Sli g ht li mitati o n  
2 = M o derate li mitati o n  
3 = Sic k at h o me 4 = Be d ri d de n 
T he occ urre nce of a defi niti ve verti g o e pis o de f or a gi ve n da y is defi ne d as a rec or de d Verti g o 
Se verit y Sc ore of [ADDRESS_422657] attac k s h o ul d be sc ore d. 
8. 2. 2.  P atie nt Gl o b al I m pressi o n of C h a n ge ( P GI C)  
T he P GI C is  a patie nt -re p orte d o utc o me t hat e val uates t he c ha n ge i n o verall “ gl o bal” Me niere’s 
disease stat us as percei ve d b y t he s u bject.  T he s u bject is as ke d: “ Si nce t he be gi n ni n g of t he cli nical st u d y, h o w w o ul d y o u rate y o ur Me niere’s disease?”.  T he be gi n ni n g o f t he cli nical st u d y 
i n t his c o nte xt is t he ti me pri or t o st u d y dr u g a d mi nistrati o n.  T he 7 res p o nse cate g ories (a n d 
p oi nt sc ores) f or t he P GI C are:  
•  Ver y m uc h w orse = - 3 
•  M uc h w orse = - 2 
•  Mi ni mall y w orse = - 1 •  U nc ha n ge d = 0 
•  Mi ni mall y i m pr o ve d = + 1 
•  M uc h i m pr o v e d = + 2 •  Ver y m uc h i m pr o ve d = + 3  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 3 6   
 8. 2. 3.  S h ort F or m 3 6 ( S F -3 6) He alt h S ur ve y – S oci al F u ncti o ni n g S u bsc ale  
T he S F - 3 6 is a vali date d, 3 6-ite m, m ulti- p ur p ose, s h ort-f or m healt h s ur ve y ( Ware et al., 1 9 9 3; 
Ware et al., 1 9 9 4).  It c o nsists of 8 s u bscales, b ut o nl y t he S ocial F u ncti o ni n g S u bscale 
c o nsisti n g of 2 q uesti o ns will be a d mi nistere d. 
T he 2 q uesti o ns of t he S ocial F u ncti o ni n g S u bscale are: 
1)  D uri n g t he past 4 wee ks, t o w hat e xte nt has y o ur p h ysical healt h or e m oti o nal pr o ble ms 
i nterfere d wit h y o ur n or mal s ocial acti vities wit h fa mil y, frie n ds, nei g h b ors, or gr o u ps? 
o  1 – N ot at all 
o  2 – Sli g htl y  
o  3 – M o deratel y  
o  4 – Q uite a bit  
o  5 – E xtre mel y  
2)  D uri n g t he past 4 wee ks, h o w m uc h of t he ti me has y o ur p h ysical healt h or e m oti o nal 
pr o ble ms i nterfere d wit h y o ur s ocial acti vities (li ke visiti n g wit h frie n ds, relati ves, etc.)?  
o  1 – All of t he ti me  
o  2 – M ost of t he ti me  
o  3 – S o me of t he ti me  o  4 – A little of t he ti me  
o  5 – N o ne of t he ti me 
8. 3.  S afet y E v al u ati o ns  
Safet y assess me nts i ncl u de : 
•  Vital S i g ns a n d Wei g ht M eas ure me nts 
•  Cli nical La b orat or y Test s •  T y m pa n o metr y 
•  A u di o metr y 
•  Ot osc o p y  •  C- S S R S Assess me nt  
•  C o nc o mita nt Me dicati o ns  
•  A d verse e ve nts (see Secti o n  9) 
8. 3. 1.  Vit al Si g n s, Hei g ht a n d Wei g ht Me as ure me nts 
Vital si g n meas ure me nts (i ncl u di n g s yst olic a n d diast olic bl o o d press ure a n d p ulse rate) will be 
c ollecte d at all st u d y visits.  Vital si g ns  will be meas ure d after s u bjects ha ve bee n seate d f or 5 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422658] at Visits 2 a n d 5. 
T he bl o o d a n d uri ne sa m ples will be use d f or t he f oll o wi n g tests: 
He mat ol o g y: w hite bl o o d cell c o u nt wit h differe ntial, he m o gl o bi n, he mat ocrit, platelet c o u nt, 
re d bl o o d cell c o u nt, mea n c or p usc ular v ol u me, mea n c or p usc ular he m o gl o bi n, a n d mea n c or p usc ular he m o gl o bi n c o nce ntrati o n.  
Ser u m C he mistr y:  al b u mi n, al kali ne p h os p hatase, ala ni ne a mi n otra nsferase ( A L T), as partate 
a mi n otra nsferase ( A S T), bl o o d urea nitr o ge n, car b o n di o xi de, calci u m, c hl ori de, creati ni ne, gl uc ose, lactate de h y dr o ge nase, p h os p h or us, p otassi u m, s o di u m, t otal bilir u bi n, t otal pr otei n. 
Uri nal ysis:  a p peara nce, c ol or, gl uc ose, ket o nes, nitrite, p H, pr otei n, s pecific gra vit y, occ ult 
bl o o d, le u k oc yte esterase, a n d ur o bili n o ge n. 
8. 3. 3.  T y m p a n o metr y 
T y m pa n o metr y assess me nts will be use d t o assess t he m o bilit y a n d c o m plia nce of t he t y m pa nic 
me m bra ne, press ure a n d v ol u me i n t he mi d dle ear, a n d f u ncti o n of t he t y m pa nic me m bra ne, 
o ssicles a n d e ustac hia n t u be.  T y m pa n o gra ms will be c o m plete d i n b ot h ears at all st u d y visits , u nless t he e xa mi ner deter mi nes t hat t here is a c o ntrai n dicati o n t o perf or mi n g t he pr oce d ure .  
S u bjects weari n g heari n g ai ds s h o ul d be i nstr ucte d n ot t o wear t heir heari n g ai ds d uri n g t he 
t y m pa n o metr y assess me nt. 
8. 3. 4.  A u di o metr y  
A u di o metric assess me nts will be use d t o assess heari n g f u ncti o n i n b ot h ears.  A u di o gra ms 
s h o ul d be c o n d ucte d at [ADDRESS_422659] u d y visits ( Baseli ne, Wee k 4, Wee k 8, a n d Wee k 1 2) f or air c o n d ucti o n a n d at [ADDRESS_422660] be c o n d ucte d i n acc or da nce wit h A merica n -S peec h - La n g ua ge-
Heari n g Ass ociati o n G ui deli nes ( A S H A, 2 0 0 5 ).  E q ui p me nt cali brati o n m ust be c urre nt a n d d oc u me nte d.  T he a u di o metric assess me nts m ust be c o n d ucte d b y a lice nse d or certifie d 
a u di ol o gist or a q ualifie d assista nt wit h a p pr o priate trai ni n g u n der t he direct s u per visi o n of a 
lice nse d or certifie d  a u di ol o gist. 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422661] u d y.   
8. 3. 6.  C ol u m bi a S uici de Se verit y R ati n g Sc ale ( C -S S R S)  Assess me nt  
T he C -S S R S is a scale t hat ca pt ures t he occ urre nce, se verit y, a n d fre q ue nc y of s uici de-relate d 
t h o u g hts a n d be ha vi ors d uri n g t he assess me nt peri o d (P os ner 2 0 1 1 ).  T he U. S. F o o d a n d Dr u g 
A d mi nistrati o n re q uires t hat a pr os pecti ve assess me nt f or s uici dal i de ati o n a n d be ha vi or be 
i ncl u de d i n cli nical trials i n v ol vi n g all dr u gs a n d bi ol o gical pr o d ucts f or ne ur ol o gical i n dicati o ns.  
T his is tr ue w het her or n ot a partic ular pr o d uct is k n o w n or s us pecte d t o be ass ociate d wit h 
treat me nt-e mer ge nt s uici dal i deati o n a n d be ha vi or.  T he C- S S R S assess me nt f ulfills t his 
re q uire me nt.  T he C-S S R S assess me nt will be a d mi nistere d at all st u d y visits.  T he Baseli ne versi o n will be use d at Visit [ADDRESS_422662] wit h a p ositi ve sc ore at Baseli ne ( Scree ni n g) or a n a p peara nce 
of a n y ne w s uici dal i deati o n or s uici de be ha vi or si nce Baseli ne s h o ul d be referre d t o t heir pri mar y care pr o vi der f or f oll o w - u p. 
If a s u bject has a n y p ost-Scree ni n g C -S S R S sc or e of 1- 3 f or I deati o n (i.e., a “ yes” a ns wer t o 
Q uesti o ns 1, 2, or 3) or a “ yes” res p o nse t o t he N o n- S uici dal Self -I nj uri o us Be ha vi or q uesti o n) a n d t he sc ore is hi g her t ha n t he Scree ni n g C- S S R S sc ore, t he n t his assess me nt s h o ul d be 
rec or de d as a n A E.  T his i nf or mati o n is re p orte d as i n dicate d i n Secti o n  9. ( P ossi ble A E ter ms: 
S uici dal pla ns, S uici dal i deati o n, S uici dal te n de nc y, S uici dal be ha vi or, S uici dal i nte nti o n, S uici dal de pressi o n, Acti ve s uici dal i deati o n, Passi ve s uici dal i deati o n, Self- i nj uri o us be ha vi or 
wit h o ut s uici dal i nte nt).  
If a s u bject has a n y p ost-Scree ni n g C - S S R S sc ore of 4 or 5 f or I deati o n (i.e., a “ yes” a ns wer t o 
q uesti o n 4 or 5) a n d/ or a n y q uesti o ns a ns were d yes f or S uici dal Be ha vi or ( wit h t he e xce pti o n of 
a “ yes” res p o nse t o t he N o n -S uici dal Self -I nj uri o us Be ha vi or q uesti o n), a n d t his was n ot 
o bser ve d at Scree ni n g, t he n t his assess me nt s h o ul d be rec or de d as a Seri o us A d verse E ve nt ( S A E).  T his i nf or mati o n is re p orte d as i n dicate d i n Secti o n  9. 2. 2. 
9.  A D V E R S E E V E N T R E P O R TI N G  
Ti mel y, acc urate, a n d c o m plete re p orti n g a n d a nal ysis of safet y i nf or mati o n fr o m cli nical trials will be c o n d ucte d i n acc or da nce wit h G o o d Cli nical Practice. 
All A Es , i ncl u di n g seri o us a d verse e ve nts ( S A Es) re p orte d or o bser ve d d uri n g or after d osi n g 
wit h t he st u d y dr u g will be rec or de d o n t he A E pa ge of t he e C R F  f or all e nr olle d s u bjects.  I nf or mati o n t o be c ollecte d i ncl u des descri pti o n  of e ve nt, date of o nset, I n vesti gat or- s pecifie d 
assess me nt of t he se verit y a n d relati o ns hi p t o st u d y dr u g, date of res ol uti o n of t he e ve nt, 
seri o us ness, a n y req uire d treat me nt or e val uati o ns, a n d o utc o me.  A d verse e ve nts res ulti n g fr o m c o nc urre nt ill nesses, reacti o ns t o c o nc urre nt ill nesses, reacti o ns t o c o nc urre nt me dicati o ns, or 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422663] u g, it s h o ul d be 
rec or de d as a n A E. 
9. 1.  A d verse E ve nt Cl assific ati o n Defi niti o ns  
A d verse E ve nt:  
A n A E is a n y u nfa v ora ble a n d u ni nte n de d dia g n osis, s y m pt o m, si g n, s y n dr o me or disease w hic h 
occ urs d uri n g t he st u d y, ha vi n g bee n a bse nt at baseli ne, or, if prese nt at baseli ne, a p pears t o 
w orse n. 
T his i ncl u des a n y occ urre nce t hat is ne w i n o nset or a g gra vate d i n se verit y or fre q ue nc y fr o m t he 
baseli ne c o n diti o n, i ncl u di n g a b n or mal res ults of dia g n ostic pr oce d ures a n d/ or la b orat or y test 
a b n or malities, w hic h are c o nsi dere d A Es if t he y: 
•  res ult i n disc o nti n uati o n fr o m t he st u d y 
•  re q uire treat me nt or a n y ot her t hera pe utic i nter ve nti o n 
•  re q uire f urt her dia g n ostic e val uati o n (e xcl u di n g a re petiti o n of t he sa me pr oce d ure t o 
c o nfir m t he a b n or malit y)  
•  are ass ociate d wit h cli nical si g ns or s y m pt o ms j u d ge d b y t he In vesti gat or t o ha v e a 
si g nifica nt cli nical i m pact 
Seri o us A d verse E ve nt ( S A E):  
A n S A E is defi ne d as a n y u nt o war d me dical occ urre nce t hat: 
•  res ults i n deat h, 
•  is life-t hreate ni n g ( N ote: t he ter m “life-t hreate ni n g” refers t o a n e ve nt i n w hic h t he 
s u bject was at ris k of deat h at t he ti me of t he e ve nt rat her t ha n t o a n e ve nt w hic h 
h y p ot heticall y mi g ht ha ve ca use d deat h if it were m ore se vere.),  
•  re q uires i n-patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n,  
•  res ults i n persiste nt or si g nifica nt disa bilit y/i nca pacity, or 
•  is a c o n ge nital a n o mal y/ birt h defect. 
Me dical a n d scie ntific j u d g me nt s h o ul d be e xercise d i n deci di n g w het her e x pe dite d re p orti n g is 
a p pr o priate i n ot her sit uati o ns, s uc h as i m p orta nt me dical e ve nts t hat ma y n ot be i m me diatel y 
life-t hreate ni n g or res ult i n deat h or h os pi[INVESTIGATOR_1314] o n b ut ma y je o par dize t he s u bject or ma y re q uire i nter ve nti o n t o pre ve nt o ne of t he ot her o utc o mes liste d i n t he a b o ve defi niti o n.  T hese e ve nts 
s h o ul d be c o nsi dere d seri o us. 
9. 1. 1.  Assess me nt of Se verit y  
T he In vesti gat or will assess t he i nte nsit y of t he A E a n d rate t he A E as mil d, m o derate, or se vere 
usi n g t he f oll o wi n g criteria:  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 4 0   
 Gr a de 1 – Mil d:  T hese e ve nts are easil y t olerate d, re q uire mi ni mal or n o treat me nt, a n d d o 
n ot i nterfere wit h t he s u bject’s dail y acti vities.  
Gr a de 2 – M o der ate:  T hese e ve nts ca use s ufficie nt disc o mf ort t o i nterfere wit h dail y 
acti vit y a n d/ or re q uire a si m ple d ose of me dicati o n, e. g., a nal gesics or a nti -e metics. 
Gr a de 3 – Se vere:  T hese e ve nts i nca pacitate a n d pre ve nt us ual acti vit y or re q uire c o m ple x 
me dicati o n/treat me nt or h os pi[INVESTIGATOR_1314] o n.  
Gr a de 4 – Life T hre ate ni n g:  T hese e ve nts are t h ose f or w hic h t he s u bject was at ris k of 
deat h at t he ti me of t he e ve nt rat her t ha n a n e ve nt w hic h h y p ot heticall y mi g ht ha ve ca use d 
deat h if it were m ore se vere.  
Gr a de 5 – De at h : T he e ve nt res ulte d i n t he deat h of t he s u bject. 
C ha n ges i n t he se verit y of a n A E s h o ul d be d oc u me nte d t o all o w f or a n assess me nt of t he 
d urati o n of t he e ve nt at eac h le vel of i nte nsit y t o be perf or me d.  
9. 1. 2.  Assess me nt of C a us alit y  
T he In vesti gat or’s assess me nt of a n A E’s relati o ns hi p t o st u d y dr u g will be part of t he 
d oc u me ntati o n pr ocess, b ut will n ot be a fact or i n deter mi ni n g w hat is or is n ot re p orte d i n t he 
st u d y.   
T he In vesti gat or will assess t he relati o ns hi p or ass ociati o n of t he  st u d y dr u g i n ca usi n g or 
c o ntri b uti n g t o t he A E, w hic h will be c haracterize d usi n g t he f oll o wi n g classificati o n a n d 
criteria: 
Defi nite:  A d verse e ve nts t hat, after caref ul me dical e val uati o n, are c o nsi dere d defi nitel y 
relate d t o t he st u d y dr u g; ot her c o n diti o ns (c o nc urre nt ill ness, pr o gressi o n/e x pressi o n of 
disease state, or c o nc urre nt me dicati o n reacti o n) d o n ot a p pear t o e x plai n t he e ve nt. 
Pr o b a ble:  A d verse e ve nts t hat, after caref ul me dical e val uati o n, are c o nsi dere d wit h a hi g h 
de gree of certai nt y t o be  relate d t o t he st u d y dr u g.  T he f oll o wi n g c haracteristics will a p pl y: 
•  a reas o na ble te m p oral relati o ns hi p e xists bet wee n t he e ve nt a n d e x p os ure t o t he st u d y 
dr u g, a n d 
•  t he e ve nt is a k n o w n reacti o n t o t he st u d y dr u g t hat ca n n ot be e x plai ne d b y a n 
alter nati ve ca use c o m m o nl y occ urri n g i n t he p o p ulati o n/i n di vi d ual, or 
•  t he e ve nt is n ot a k n o w n reacti o n t o t he st u d y dr u g b ut ca n n ot be reas o na bl y 
e x plai ne d b y a n alter nati ve ca use.  
P ossi ble:  A d verse e ve nts t hat, after caref ul me dical e val uati o n, d o n ot meet t he criteria f or a defi nite or pr o ba ble relati o ns hi p t o t he st u d y dr u g, b ut f or w hic h a c o n necti o n ca n n ot be r ule d o ut wit h certai nt y.  T he f oll o wi n g c haracteristics will a p pl y:  
•  t he e ve nt occ urs after e x p os ure t o t he st u d y dr u g, a n d 
•  t here is a reas o na ble te m p oral relati o ns hi p t o t he a p plicati o n, b ut t he e ve nt is n ot a 
k n o w n reacti o n t o t he st u d y dr u g a n d c o ul d be e x plai ne d b y a c o m m o nl y occ urri n g 
alter nati ve ca use, or  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 4 1   
 •  i n t he a bse nce of a reas o na ble te m p oral relati o ns hi p, t he e ve nt ca n n ot be e x plai ne d b y 
a n alter nati ve ca use.  
N ot rel ate d:  A d verse e ve nts i n t his cate g or y will ha ve eit her of t he f oll o wi n g c haracteristics:  
•  t he e ve nt d oes n ot ha ve a reas o na ble te m p oral relati o ns hi p t o st u d y dr u g 
a d mi nistrati o n a n d/ or ca n be e x plai ne d b y a c o m m o nl y occ urri n g alter nati ve ca use. 
9. 1. 3.  F oll o w u p of A d verse E ve nts  
T he In vesti gat or will f oll o w a n o n -seri o us A E u ntil res ol uti o n, sta bilizati o n, or t he E n d of St u d y 
Visit.  T he In vesti gat or will f oll o w a n S A E (re gar dless of relati o ns hi p t o st u d y dr u g) u ntil t he e ve nt res ol ves, sta bilize s, or bec o mes n o n-seri o us.  All A Es i de ntifie d o n t he last sc he d ule d 
c o ntact m ust be rec or de d o n t he A E pa ge of t he e C R F a n d t he c urre nt stat us ( o n g oi n g or 
res ol ve d) will be n ote d.  I n a d diti o n, S A Es will be re p orte d t o Dr u g Safet y acc or di n g t o t he re p ortin g g ui deli nes i de ntifie d i n  Secti o n  9. 2. 2. 
9. 2.  M o nit ori n g of A d verse E ve nts  
9. 2. 1.  All A d verse E ve nts  
All A Es will be a nal yze d f or safet y.  T h ose meeti n g t he defi niti o n of S A E m ust be re p orte d usi n g 
t he S A E F or m.  S u bjects s h o ul d v ol u ntaril y re p ort a n y A Es or re p ort A Es i n res p o nse t o ge neral, 
n o n- directe d q uesti o ni n g (e. g., " H o w has y o ur healt h bee n si nce t he last visit?").  F or eac h A E 
v ol u nteere d b y t he s u bject, t he I n vesti gat or s h o ul d o btai n all t he i nf or mati o n re q uire d t o c o m plete t he A E pa ge of t he e C R F, i n acc or da nce wit h t he g ui deli nes t hat acc o m pa n y it.  
All A Es, re gar dless of seri o us ness, se verit y, or pres u me d relati o ns hi p t o st u d y t hera p y, m ust be 
rec or de d usi n g me dical ter mi n ol o g y i n t he s o urce d oc u me nt a n d o n t he e C R F.  W he ne ver p ossi ble, dia g n oses s h o ul d be gi ve n w he n si g ns a n d s y m pt o ms are d ue t o a c o m m o n eti ol o g y 
(e. g., c o u g h, r u n n y n ose, s neezi n g, s ore t hr oat, a n d hea d c o n gesti o n s h o ul d be re p orte d as " u p per 
res pi[INVESTIGATOR_1305] y i nfecti o n").  I n vesti gat ors m ust rec or d o n t he e C R F t heir o pi [INVESTIGATOR_9384] o n c o ncer ni n g t he relati o ns hi p of t he A E t o st u d y t hera p y.  All meas ures re q uire d f or A E ma na ge me nt m ust be 
rec or de d i n t he s o urce d oc u me nt a n d re p orte d acc or di n g t o s p o nsor i nstr ucti o ns.  
A n y n o n-seri o us A E t hat occ urs after t he d ose of st u d y dr u g m ust be re p orte d i n detail o n t he 
a p pr o priate e C R F pa ge a n d f oll o we d u ntil res ol uti o n, sta bilizati o n, or t he E n d of St u d y Visit.  
T he descri pti o n of t he A E will i ncl u de descri pti o n of e ve nt, date of o nset, date of res ol uti o n, 
I n vesti gat or assess me nt of se verit y a n d relati o ns hi p t o st u d y dr u g, seri o us ness, a n y re q uire d treat me nt or e val uati o ns, a n d o utc o me.  
T he S p o ns or ass u mes res p o nsi bilit y f or a p pr o priate re p orti n g of A Es t o t he re g ulat or y 
a ut h orities.  T he S p o ns or will als o re p ort t o t he In vesti gat ors all seri o us A Es t hat are u nliste d a n d ass ociate d wit h t he use of t he dr u g.  T he I n vesti gat ors m ust re p ort t hese e ve nts t o t he a p pr o priate 
I nstit uti o nal Re vie w B oar d (I R B) or Researc h Et hics C o m mittee  (R E C ) i n acc or da nce wit h l ocal 
re g ulati o ns. 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422664]-t o-f oll o w- u p bef ore c o m pleti o n of Visit 5 ( Wee k 1 2) will n ot be c o nsi dere d t o ha ve c o m plete d t he st u d y. 
[ADDRESS_422665] u d y e val uati o ns at a n y ti me, f or a n y reas o n , wit h o ut prej u dice; n o net heless, I n vesti gat ors s h o ul d atte m pt t o e nc o ura ge s u bjects t o c o m plete 
t he pr ot oc ol s o t hat c o nti n ue d o bser vati o n a n d f oll o w- u p meas ure me nts ma y be o btai ne d.   
S u bjects m ust be wit h dra w n fr o m t he st u d y f or a n y of t he f oll o wi n g:  
•  Wi t h dra wal of c o nse nt 
•  T he s u bject is u n willi n g or u na ble t o c o m pl y wit h t he pr ot oc ol 
Ot her reas o ns f or wit h dra wal of s u bjects fr o m t he st u d y mi g ht i ncl u de:  
•  At t he discreti o n of t he I n vesti gat or f or me dical reas o ns  •  At t he discreti o n of t he I n vesti gat or or S p o ns or f or n o nc o m plia nce 
•  Si g nifica nt pr ot oc ol de viati o n  •  Decisi o n b y t he I n vesti gat or or S p o ns or 
At a n y p oi nt, t he I n vesti gat or ma y disc o nti n ue t he s u bject’s st u d y partici pati o n at t he discreti o n 
of t he I n vesti gat or or at t he re q uest of t he s u bject, a n d e ns ure t he s u bject recei ves a p pr o priate me dical care; t he I n vesti gat or ma y als o c o ns ult t he me dical m o nit or t o disc uss o ut- of -ra n ge test 
res ults. 
[ADDRESS_422666] u d y/ Earl y -Ter mi nati o n assess me nts.  
W he n a s u bject wit h dra ws fr o m t he st u d y pri or t o c o m pleti n g t he E n d- of- St u d y Visit, t he reas o n 
f or wit h dra wal is t o be d oc u me nte d o n t he e C R Fs a n d i n t he s o urce d oc u me nt. 
[ADDRESS_422667] d. 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422668] t he h y p ot hesis t hat s u bjects ra n d o mize d t o 
O T O -1 0 4 will de m o nstrate fe wer defi niti ve verti g o da ys ( D V D) t ha n s u bjects ra n d o mize d t o 
place b o at Wee k 1 2 (t he 4 -wee k  ( 2 8- da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2).  T he mai n sec o n dar y o bjecti ve of t he st u d y is t o i n vesti gate t he safet y pr ofile of a [ADDRESS_422669] b o w he n a d mi nistere d as a si n gle i ntrat y m pa nic i njecti o n i n s u bjects wit h 
Me niere’s disease.  
T he f oll o wi n g statistical secti o ns descri be t he ge neral a nal ytic met h o ds t o be i m ple me nte d t o 
assess t he o verall st u d y o bjecti ves.  M ore detaile d descri pti o ns of t he met h o d ol o g y will be 
pr o vi de d i n t he Statistical A nal ysis Pla n ( S A P).  T he S A P will be pre pare d a n d fi na lize d bef ore u n bli n di n g t he s u bjects’ ra n d o mize d treat me nt assi g n me nts.  
[ADDRESS_422670] u d y is 1 4 2 s u bjects ra n d o mize d wit h 1: [ADDRESS_422671] u g: place b o, wit h 7 1 i n eac h gr o u p.   
T he p o wer esti mate was base d o n t he esti mate d treat me nt gr o u p mea ns f or D V D at Wee k 1 2 [t he 
4- wee k ( 2 8- da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2] fr o m pre vi o usl y c o n d ucte d trials b y t he S p o ns or i n t his i n dicati o n.  T he pri mar y a nal ysis will  be c o n d ucte d usi n g a Ne gati ve Bi n o mial m o del at Wee k 1 2.  F or t he Ne gati ve Bi n o mial a nal ysis, a sa m ple size of 1 4 2  s u bjects will pr o vi de a p pr o xi matel y 9 0 % p o wer t o detect a differe nce bet wee n gr o u ps i n t he [ADDRESS_422672] u d y O T O- 1 0 4- 2 0 1 5 0 8 ( data o n file). T he calc ulati o ns were c o n d ucte d usi n g E A S T v 6. [ADDRESS_422673] u d y.    
F ull A n al ysis Set ( F A S):   T he f ull a nal ysis set will i ncl u de all s u bjects w h o are ra n d o mize d, 
recei ve st u d y dr u g, ha ve a baseli ne defi niti ve verti g o meas ure me nt  f or t he 4-wee k lea d -i n 
peri o d a n d at least o ne p ost - baseli ne dail y diar y e ntr y  f or Wee k [ADDRESS_422674] u g recei ve d. 
Per Pr ot oc ol A n al ysis Set:   T he per pr ot oc ol a nal ysis set will i ncl u de all s u bjects w h o are 
ra n d o mize d, recei ve st u d y dr u g, meet eli gi bilit y criteria, ha ve n o maj or pr ot oc ol de viati o ns,  
a n d ha ve a baseli ne defi niti ve verti g o meas ure me nt a n d at least o ne p ost- baseli ne  dail y diar y 
e ntr y wit hi n Wee k [ADDRESS_422675] u g recei ve d. 
I nte nt-t o-Tre at A n al ysis Set (I T T):  T he I T T a nal ysis set will i ncl u de all ra n d o mize d 
s u bjects w h o recei ve st u d y dr u g.  S u bjects will be i ncl u de d i n t he treat me nt gr o u p t o w hic h t he y were ra n d o mize d re gar dless of t he act ual st u d y dr u g recei ve d. T he I T T set will be use d 
t o assess se nsiti vit y t o missi n g data.
  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 4 5   
 Safet y A nal ysis Set:  T he safet y a nal ysis set will i ncl u de all  s u bjects w h o recei ve st u d y dr u g.  
S u bjects will be i ncl u de d i n t he treat me nt gr o u p acc or di n g t o t he act ual treat me nt recei ve d 
re gar dless of t heir ra n d o mize d assi g n me nt.  W he n t he ear is t he u nit of a nal ysis, t he safet y 
a nal ysis will cate g orize a n ear b y w het her it was a treate d or a n u ntreate d ear, irres pecti ve of w het her it was t he affecte d ear.  
1 1. 3.  Descri pti o n of S u b gr o u ps t o be A n al yze d  
Des cri pti ve a nal yses will be perf or me d f or t he pri mar y efficac y e n d p oi nt f or t he f oll o wi n g s u b gr o u ps usi n g t he F A S wit h details pr o vi de d i n t he Statistical A nal ysis Pla n ( S A P ): 
•  S u bject De m o gra p hics 
−  Ge n der 
−  Race/ Et h nicit y  
−  A ge (cate g ories:  1 8 -3 0, 3 1 - 4 0, 4 1- 6 0, 6 1- 6 4, 6 5- 7 4, 7 5- 8 4, ≥ 8 5 yrs.) 
•  Baseli ne Disease C haracteristics  
−  D urati o n of Me niere’s Disease  −  De gree of heari n g l oss  
−  Beta histi ne use  
[ADDRESS_422676] dis p ositi o n 
will be pr o vi de d.   
1 1. 5.  Effic ac y E v al u ati o ns  
1 1. 5. 1.  Pri m ar y Effic ac y E n d p oi nt  
T he pri mar y efficac y e n d p oi nt is t he 2 8- da y a vera ge defi niti ve verti g o da ys ( D V D) at Wee k 1 2 
(t he 4-wee k  ( 2 8- da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2).  A D V D is defi ne d as eac h da y t he s u bject rec or de d a verti g o e pis o de lasti n g at least [ADDRESS_422677] e pis o de i n ter ms of 
sc ore s h o ul d be rec or de d
.   
1 1. 5. 2.  Sec o n d ar y Effic ac y E n d p oi nts  
Sec o n dar y Efficac y E n d p oi nt: 
•  Se verit y of verti g o e pis o des as meas ure d b y t he M ea n Se verit y Verti g o Sc ore  ( M S V S) at 
Wee k 1 2 (t he 4 -wee k ( 2 8 - da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2) 
•  T he 2 8- da y a vera ge of n u m ber of da ys Sic k at h o me or Be dri d de n ( D S B) as a 
c o nse q ue nce of verti g o at Wee k 1 2 (t he 4- wee k ( 2 8- da y) i nter val fr o m Wee k 9 t hr o u g h 
Wee k 1 2) 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 4 6   
 •  Perce nt of s u bjects ac hie vi n g a 7 5 % re d ucti o n fr o m baseli ne i n 2 8- da y a vera ge D V D at 
Wee k 1 2  
•  Perce nt of s u bject s ac hie vi n g a 1 0 0 % re d ucti o n fr o m baseli ne (i.e., c o u nt of zer o) i n 2 8-
da y a vera ge D V D at Wee k 1 2  
•  T he c ha n ge fr o m baseli ne i n verti g o fre q ue nc y ( V F) at Wee k 1 2 (t he 4- wee k st u d y 
i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2), w here verti g o fre q ue nc y is defi ne d as t he 
n u m ber of D V Ds rec or de d d uri n g t he 4 - wee k i nter val di vi de d b y t he n u m ber of n o n-missi n g diar y e ntries f or t he rele va nt i nter val  
•  A vera ge dail y c o u nt of verti g o e pis o des at Wee k 1 2 (t he 4 -wee k ( 2 8- da y) i nter val fr o m 
Wee k 9 t hr o u g h Wee k 1 2) 
[ADDRESS_422678] orat or y Efficac y E n d p oi nt s are: 
•  T he c ha n ge fr o m baseli ne i n verti g o fre q ue nc y ( V F) at Wee k 8, w here verti g o fre q ue nc y 
is defi ne d as t he n u m ber of D V Ds  rec or de d d uri n g t he 4- wee k i nter val di vi de d b y t he 
n u m ber of n o n- missi n g diar y e ntries f or t he rele va nt i nter val  
•  Se verit y of verti g o e pis o des as meas ure d b y t he M ea n Se verit y Verti g o Sc ore  ( M S V S) at 
Wee k  8  
•  A vera ge dail y c o u nt of verti g o e pis o des at Wee k 8  
•  T he [ADDRESS_422679] u d y i nter val  (i.e., Wee k 4 , Wee k 8 , Wee k 1 2) 
•  T he n u m ber of 2 8- da y a vera ge defi niti ve verti g o d a ys ( D V D) at Wee k 8  •  Patie nt Gl o bal I m pressi o n of C ha n ge ( P GI C) at Wee ks 8 a n d 1 2 •  S F - 3 6 S ocial F u ncti o ni n g S u bscale at Wee ks 8 a n d 1 2 
Occ urre nce of N or mal acti vit y, Sli g ht li mitati o n, M o derate li mitati o n, Sic k at h o me, a n d Be dri d de n 
e ve nts as a c o nse q ue nce of verti g o at Wee k 4, Wee k 8, a n d Wee k 1 2  Details re gar di n g i m p utati o n 
of missi n g data, i ncl u di n g ite ms f or q uesti o n naires, will be pr o vi de d i n t he Statistical 
A nal ysis Pla n ( S A P).  
1 1. 5. 4.  A n al ytic Met h o ds f or Effi c ac y 
T he pri mar y efficac y e n d p oi nt, t h e 2 8-da y a vera ge D V D at Wee k 1 2 (t he 4 -wee k i nter val  fr o m 
Wee k 9 t hr o u g h Wee k 1 2), will be c o m pare d bet wee n O T O- [ADDRESS_422680] b o at t he 2-taile d, 0. 0 5 
al p ha le vel usi n g a Ne gati ve Bi n o mial m o del. T his m o del will i ncl u de fi xe d effects f or 
ra n d o mize d treat me nt gr o u p ( O T O- [ADDRESS_422681] b o) a n d se x ( male vs. fe male), wit h t he [ADDRESS_422682] u d y is f ull a nal ysis set ( F A S).  S u bjects will be i ncl u de d i n t he 
treat me nt gr o u p t o w hic h t he y were ra n d o mize d re gar dless of t he act ual st u d y dr u g recei ve d. 
T he pri mar y e n d p oi nt a nal ysis als o will be c o n d ucte d usi n g per- pr ot oc ol  a n d I T T  a nal ysis sets 
as se nsiti vit y a nal yses .   
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 4 7   
 T he ke y sec o n dar y efficac y e n d p oi nt of t he Mea n Se verit y Verti g o Sc ore ( M S V S) f or Wee k 1 2 
( Wee k 9 t hr o u g h Wee k 1 2) will be a nal yze d usi n g a n A N C O V A m o del wit h fi xe d effects of 
ra n d o mize d treat me nt, gr o u p ( O T O- [ADDRESS_422683] b o) a n d se x ( male vs. fe male), wit h t he 
s u bject’s a vera ge mea n se verit y verti g o sc ore at lea d -i n peri o d as a c o variate. 
T he ke y sec o n dar y e n d p oi nt of t he 2 8- da y a vera ge of n u m ber of da ys Sic k at h o me or Be dri d de n 
( D S B) as a c o nse q ue nce of verti g o at Wee k 1 2 will be c o m pare d bet wee n t he treat me nt gr o u ps usi n g usi n g t he sa me Ne gati ve Bi n o mial m o del as s pecifie d f or t he pri mar y a nal ysis a n d usi n g t he 2 8-da y a vera ge Lea d -i n D S B  as a c o variate.   T he m o del will i ncl u de fi xe d effects f or ra n d o mize d treat me nt gr o u p ( O T O- [ADDRESS_422684] b o) a n d se x ( male vs. fe male).   
T he ke y sec o n dar y e n d p oi nts of perce nt of s u bjects ac hie vi n g a 7 5 % a n d a 1 0 0 % (i.e., c o u nt of 
zer o)  re d ucti o n fr o m baseli ne i n [ADDRESS_422685]. T he ris k differe nce a n d t he 9 5 % CI ar o u n d t he ris k differe nce will als o be pr o vi de d. 
T he sec o n dar y efficac y e n d p oi nt of c ha n ge fr o m baseli ne i n verti g o fre q ue nc y ( V F) at Wee k 1 2 
(t he 4- wee k i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2), will be a n al yze d usi n g a n A N C O V A 
m o del wit h treat me nt as a fi xe d effect a n d  se x as fi xe d effects wit h t he lea d-i n peri o d V F as a 
c o variate .   
T he sec o n dar y efficac y e n d p oi nt of a vera ge dail y c o u nt of verti g o e pis o des d uri n g 4- wee k st u d y 
i nter val (Wee k 9 t hr o u g h Wee k 1 2) will be usi n g t he A N C O V A m o del s pecifie d f or t he
 
sec o n dar y efficac y e n d p oi nt of c ha n ge fr o m baseli ne i n V F  at Wee k [ADDRESS_422686]’s A vera ge Dail y Verti g o C o u nt ( A D V C ) at lea d-i n peri o d as a c o variate.    
Alter nati ve m o dels will be pre -s pecifie d i n t he S A P s h o ul d certai n ass u m pti o n s re gar di n g data 
a n d m o dels d o n ot h ol d.  I n a d diti o n, t he S A P will i ncl u de pre- s pecifie d data tra nsf or mati o ns 
s h o ul d e val uati o n of t he resi duals s u g gest a data tra nsf or mati o n is m ore s uita ble.  
If t he pri mar y e n d p oi nt c o m paris o n bet wee n t he t w o treat me nt gr o u ps is statisticall y si g nifica nt 
i n fa v or of O T O- 1 0 4 t he n a cl ose d testi n g, gate- kee pi n g pr oce d ure will be use d t o c o m pare t he f oll o wi n g sec o n dar y efficac y e n d p oi nts se q ue ntiall y:  
1.  Se verit y of verti g o e pis o des as meas ure d b y t he mea n Verti g o Sc ore at Wee k 1 2 (t he 4-
wee k ( 2 8- da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2) 
2.  T he  2 8-da y a vera ge  n u m ber of da ys Sic k at h o me or Be dri d de n as a c o nse q ue nce of 
verti g o at Wee k 1 2 (t he 4 - wee k ( 2 8- da y) i nter val fr o m Wee k 9 t hr o u g h Wee k 1 2) 
3.  Perce nt of s u bjects ac hie vi n g a 7 5 % re d ucti o n fr o m baseli ne i n 2 8- da y a vera ge  D V D at 
Wee k 1 2.  
4.  Perce nt of s u bjects ac hie vi n g a 1 0 0 % re d ucti o n fr o m baseli ne (i.e., c o u nt of zer o)  i n [ADDRESS_422687] sec o n dar y e n d p oi nt c o m paris o n bet wee n t he t w o treat me nt gr o u ps is 
statisticall y si g nifica nt i n fa v or of O T O- 1 0 4 t he n t he sec o n d sec o n dar y e n d p oi nt will be 
c o m pare d a n d teste d.  If t he sec o n d ke y sec o n dar y e n d p oi nt c o m paris o n bet wee n t he t w o 
treat me nt gr o u ps is teste d a n d t he res ult is statisticall y si g nifica nt i n fa v or of O T O- 1 0 4, t he n t he t hir d ke y sec o n dar y e n d p oi nt will be c o m pare d a n d teste d. If t he t hir d ke y sec o n dar y e n d p oi nt 
c o m paris o n bet wee n t he t w o treat me nt gr o u ps is teste d a n d t he res ult is statisticall y si g nifica nt i n 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422688] ke y sec o n dar y e n d p oi nt t hat d oes n ot de m o nstrate a statisticall y si g nifica nt differe nce 
bet wee n gr o u ps i n fa v or of O T O- 1 0 4, t he gate- kee pi n g pr oce d ure e n ds a n d a n y s u bse q ue nt ke y 
sec o n dar y e n d p oi nt p-val ues will be c o nsi dere d as a n o mi nal p - val ue(s).  
T he gate- kee pi n g pr oce d ure c o ntr ols t he T y pe I err or f or t he f o ur pla n ne d c o m paris o ns a n d, 
t heref ore, t here will be n o α s pe n di n g pe nalt y ass ociate d wit h t he pla n ne d ke y sec o n dar y 
c o m paris o ns. 
T he re mai ni n g sec o n dar y e n d p oi nts c o m paris o ns will n ot f oll o w t he gate- kee pi n g pr oce d ure a n d, 
t heref ore, t he re p orte d p- val ues will be re p orte d as n o mi nal p-val ues.   T hese a nal yses will be 
c o n d ucte d usi n g t he F A S o nl y. 
All efficac y h y p ot hesis tests will be 2 -si de d a n d perf or me d at α = 0. 0 5 si g nifica nce le vel, u nless 
ot her wise s pecifi d i n t he S A P . 
1 1. 6.  S afet y E v al u ati o ns  
Safet y e n d p oi nts t o be e xa mi ne d i ncl u de: 
•  Vital Si g ns a n d Wei g ht Meas ure me nts  
•  Cli nical La b orat or y Test  •  T y m pa n o me tr y 
•  A u di o metr y 
•  Ot osc o p y  •  C- S S R S Assess me nt  
•  C o nc o mita nt Me dicati o ns  
•  A d verse e ve nts  
Descri pti ve statistical ta b ulati o ns will be prese nte d f or all s u bjects i ncl u de d i n t he Safet y 
A nal ysis Set.  
1 1. 6. 1.  A d verse E ve nts  
T he c urre nt versi o n of Me dical Dicti o nar y f or Re g ulat or y Acti vities ( Me d D R A), as i n dicate d i n 
t he Data Ma na ge me nt Pla n, will be use d t o c o de all A Es. 
T he pri mar y a nal ysis of A Es will c o nsi der o nl y treat me nt -e mer ge nt A Es, e ve nts occ urri n g f or 
t he first ti me, or w orse ni n g d uri n g or after t he first d ose of st u d y dr u g.  S u bject i nci de nce of T E A Es a n d S A Es will be ta b ulate d b y preferre d ter ms a n d s yste m or ga n class.  Se verit y a n d 
relati o ns hi p t o st u d y dr u g will als o be prese nte d.  F or s u m mar y ta bles, a s u bject w h o e x perie nces 
t he sa me c o de d eve nt m ore t ha n o nce is c o u nte d o nl y o ne ti me f or t hat c o de d e ve nt at t he hi g hest 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422689] u g will be 
re p orte d i n data listi n gs.  F urt her details will be pr o vi de d i n t he S A P. 
1 1. 6. 2.  Vit al Si g ns a n d L a b or at or y P ar a meters 
T he a nal ysis of vital si g ns a n d la b orat o r y para meters will i ncl u de descri pti ve statistics f or t he 
c ha n ge fr o m baseli ne t o t he e n d p oi nt visit, c ha n ge fr o m baseli ne f or eac h visit ( vital si g ns o nl y).  
W here a p pr o priate, a nal yses will als o i ncl u de s hifts fr o m baseli ne t o t he e n d p oi nt visit.  F or 
la b orat or y val ues, t he n or mal ra n ges will be use d t o deter mi ne t he classificati o ns. Val ues bel o w 
t he n or mal ra n ge will be classifie d as l o w, val ues a b o ve t he n or mal ra n ge will be classifie d as hi g h, a n d val ues wit hi n t he n or mal ra n ge will be classifie d as n o r mal. 
[ADDRESS_422690] u d y visit will be 
ta b ulate d as t he pr o p orti o n of s u bjects wit h air mi n us b o ne c o n d ucti o n t hres h ol ds of:   
•  ≤ 1 0 d B or  
•  > [ADDRESS_422691] u d y visit will be calc ulate d f or eac h  treat me nt gr o u p.  
T y m pa n o gra m c ha n ges will i ncl u de b ot h t he t y pe of t y m pa n o gra m ( A, B- s mall v ol u me a n d/ or n or mal, B- lar ge v ol u me, or C).  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 5 0   
 1 1. 6. 6.  C ol u m bi a -S uici de Se verit y R ati n g Sc ale ( C -S S R S)  
T he C- S S R S  will be a d mi nistere d at eac h visit usi n g t he a p pr o priate v ersi o n i.e., Baseli ne or 
Si nce Last Visit. A nal ysis of t his scale will be perf or me d o n t he Safet y A nal ysis Set.  
1 1. 6. 6. 1.  B aseli ne Versi o n  
T he Baseli ne versi o n of t he C -S S R S will be a d mi nistere d at t he Scree ni n g visit ( Visit 1). T his 
versi o n of t he scale ca pt ures b o t h s uici de i deati o n a n d s uici de be ha vi or (lifeti me). T here are 5 
s uici dal i deati o n q uesti o ns, eac h ca pt ure d as yes/ n o f or t he s u bject’s lifeti me. A d diti o nall y a 
si xt h s uici dal i deati o n varia ble will be create d t o i n dicate if t here was a n y i deati o n, re gar dless of 
t y pe. T here are 4 s uici dal be ha vi or q uesti o ns, eac h ca pt ure d as yes/ n o f or t he s u bject’s lifeti me. A fift h s uici dal be ha vi or varia ble will be create d t o ca pt ure if t here was a n y s uici dal be ha vi or 
re gar dless of t y pe. A n a d diti o nal q uesti o n as ks if s uici dal be ha vi or is prese nt d uri n g t he visit. All 
s uici dal i deati o n a n d be ha vi oral varia bles as o utli ne d here will be ta b ulate d o verall a n d b y treat me nt gr o u p. All C- S S R S data will be i ncl u de d i n data listi n gs. T here is n o i ncl usi o n or 
e xcl usi o n criteri o n a ss ociate d wit h t he Baseli ne C-S S R S sc ore.  S u bjects wit h a p ositi ve sc ore 
s h o ul d be referre d t o t heir pri mar y care pr o vi der f or f oll o w-u p.  
[ADDRESS_422692] u d y visit after t he Scree ni n g visit ( Visit 1).  T he sa me o verall i n di vi d ual varia bles f or s uici dal i deati o n a n d be ha vi or will be assesse d as i n t he Baseli ne versi o n.  I n a d diti o n, o verall s uici dalit y ( yes/ n o) will be defi ne d as a n y s u bject ha vi n g a n y s uici dal i deati o n or be ha vi or si nce t he last visit.  All s uici dal i deati o n a n d be ha vi or varia bles will be ta b ulate d o verall a n d b y treat me nt gr o u p f or eac h st u d y visit, as well as s hift ta bles dis pla ys s u bjects w h o m o ve fr o m ‘ N o’ t o ‘ Yes’ at eac h st u d y visit .  All C -S S R S data will be i ncl u de d i n data listi n gs  . 
A n y s u bject wit h a n a p peara nce of a n y ne w s uici dal i deati o n or s uici de be ha vi or si nce Scree ni n g 
s h o ul d be referre d t o t heir pri mar y care pr o vi der f or f oll o w-u p.  
If a s u bject has a n y p ost-Scree ni n g C -S S R S sc ore of 1 -3 f or I deati o n (i.e., a “ yes” a ns wer t o 
Q uesti o ns 1, 2, or 3) or a “ yes” res p o nse t o t he N o n- S uici dal Self -I nj uri o us Be ha vi or q uesti o n) a n d t he sc ore is hi g her t ha n t he Sc ree ni n g C-S S R S sc ore, t he n t his assess me nt s h o ul d be 
rec or de d as a n A E .  T his i nf or mati o n is re p orte d as i n dicate d i n  Secti o n  9. 2. 1.  ( P ossi ble A E 
ter ms: S uici dal pla ns, S uici dal i deati o n, S uici dal te n de nc y, S uici dal be ha vi or, S uici dal i nte nti o n, S uici dal de pressi o n, Acti ve s uici dal i deati o n, Passi ve s uici dal i deati o n, Self- i nj uri o us be ha vi or 
wit h o ut s uici dal i nte nt).  
If a s u bject has a n y p ost-Scree ni n g C - S S R S sc ore of 4 or 5 f or I deati o n (i.e., a “ yes” a ns wer t o 
q uesti o n 4 or 5) a n d/ or a n y q uesti o ns a ns were d yes f or S uici dal Be ha vi or ( wit h t he e xce pti o n of 
a “ yes” res p o nse t o t he N o n -S uici dal Self -I nj uri o us Be ha vi or q uesti o n), a n d t his was n ot 
o bser ve d at Scree ni n g, t he n t his assess me nt s h o ul d be rec or de d as a Seri o us A d verse E ve nt.  T his i nf or mati o n is re p orte d as i n dicate d i n  Secti o n  9. 2. 2. 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422693] u d y meas ure me nts t o mi ni mize t he a m o u nt of missi n g data.  
E xce pt f or partial dates, safet y data will n ot be i m p ute d.  T he i m p utati o n al g orit h m f or partial 
dates will be defi ne d i n t he S A P. 
1 1. 8.  I nteri m A n al yses 
T here  are n o f or mal i nteri m a nal yses pla n ne d.  Bli n de d re vie w s of safet y data will be c o n d ucte d as descri be d i n Secti o n  1 4. 6; h o we ver, t he re vie w of s uc h data is n ot i nte n de d t o i m pact t he st u d y 
c o n d uct u nless t here are safet y c o ncer ns.  As s uc h, it is e x pecte d t hat t he trial will c o nti n ue t o its 
sc he d ule d c o m pleti o n barri n g a n y u ne x pecte d safet y iss ues. 
[ADDRESS_422694] u g(s)  
T he i n vesti gati o nal dr u g pr o d uct a d mi nistere d t o s u bjects i n t his st u d y will be O T O- [ADDRESS_422695] s us pe nsi o n f or d osi n g will be pre pare d fr o m t w o se parate 
c o m p o ne nts,  ( o ne vial nee de d) a n d O T O- 1 0 4 Acti ve ( o ne vial nee de d).   
A n a p pr o priate v ol u me of  will be wit h dra w n a n d deli vere d i nt o t he 
O T O - [ADDRESS_422696] u g c o nce ntrati o n of 6 0 m g/ m L.  Place b o will c o nsist of t he  ve hicle use d t o f or m ulate O T O- 1 0 4 a n d 
will be s u p plie d fr o m o ne vial ). 
T he f oll o wi n g dr u g s u p plies will be use d i n t he st u d y: 
Pr o d uct  S u p plie d as:  
O T O -1 0 4  A kit c o ntai ni n g: o ne vial of O T O -[ADDRESS_422697] b o   A kit c o ntai ni n g: o ne vial of  s ol uti o n.  
[ADDRESS_422698] b o will  be pre pare d b y a n u n bli n de d Q M P i n a clea n, sec ure l ocati o n wit h a r o o m te m perat ure prefera bl y at or bel o w 2 3° C ( 7 3° F).  T he l ocati o n will n ot be accesse d b y t he 
bli n de d pers o n nel d uri n g st u d y dr u g pre parati o n.  Please refer t o t he P har mac y Ma n ual f or 
detaile d st u d y dr u g p re parati o n i nstr ucti o ns. 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422699] ora ge i nstr ucti o ns.  A la bel 
will be affi xe d t o t he O T O - 1 0 4 Acti ve a n d 1 6 % p ol o xa mer s ol uti o n vials i n dicati n g c o nte nts a n d 
st ora ge i nstr ucti o ns.  A s yri n ge bli n di n g la bel will be pr o vi de d t o mas k t he s yri n ge c o nte nts f or 
i njecti o n. 
[ADDRESS_422700] will be ge nerate d b y t he I W R S s yste m a n d se nt t o t he cli nical s u p plies ve n d or.  U p o n 
s hi p me nt a n d recei pt of t he cli nical trial material, t he site pers o n nel (e. g., p har mac y) will 
ac k n o wle d ge t he s hi p me nt usi n g t he I W R S a n d i de ntif y a n y da ma ge d, missi n g, or u n usa ble kits s o t he y will n ot be dis pe nse d. 
[ADDRESS_422701] a n d re p ort t he kit(s) as 
u nacce pta ble f or dis pe nsi n g t o t he I W R S t o re m o ve it fr o m i n ve nt or y. 
[ADDRESS_422702] ore d a n d dis p ose d of 
acc or di n g t o t he S p o ns or's i nstr ucti o ns.  Dr u g acc o u nta bilit y will be verifie d b y t he S p o ns or's u n bli n de d st u d y m o nit or d uri n g t he c o urse of t he st u d y.  St u d y dr u g will be st ore d i n a li mite d 
access area or i n a l oc ke d refri gerat or u n der a p pr o priate e n vir o n me ntal c o n diti o ns.  
T he I n vesti gat or a grees n ot t o s u p pl y t he st u d y dr u g t o a n y pers o n ot her t ha n s u b-I n vesti gat ors, 
desi g nate d staff a n d t he s u bjects partici pati n g i n t he st u d y.  St u d y dr u g ma y n ot be rela bele d or 
reassi g ne d f or use b y ot her s u bjects e xce pt u n der s pecial circ u msta nces a p pr o ve d b y t he 
S p o ns or. 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422703] u d y is perf or me d i n acc or da nce 
wit h t he pr ot oc ol, t he Declarati o n of Helsi n ki, as well as wit h t he N ote f or G ui da nce o n G o o d Cli nical Practice (I C H/ 1 3 5/ 9 5), a n d a p plica ble re g ulat or y re q uire me nts.  T h ese d oc u me nts set 
f ort h t hat t he i nf or me d c o nse nt of t he s u bjects is a n esse ntial prec o n diti o n f or partici pati o n i n t he 
cli nical st u d y.  
1 3. 2.  I nstit uti o n al Re vie w B o ar d (I R B) a n d Rese arc h Et hics C o m mittee  
(R E C ) 
T his trial will be u n derta ke n o nl y after f ull a p pr o val of t he pr ot oc ol a n d a d de n da has bee n o btai ne d fr o m a desi g nate d I R B or R E C a n d t he s p o ns or has recei ve d a c o p y of t his a p pr o val. 
T he I R B or R E C m ust be i nf or me d of all s u bse q ue nt pr ot oc ol a me n d me nts iss ue d b y t he 
s p o ns or. 
Re p orts o n, a n d re vie ws of, t he trial a n d its pr o gress will be s u b mitte d t o t he I R B or R E C b y t he 
In vesti gat or at i nter vals sti p ulate d i n t heir g ui deli nes.  
[ADDRESS_422704] u d y has bee n f ull y e x plai ne d.  T he c o nse nt f or m is 
t y pi[INVESTIGATOR_1306] y si g ne d at t he Scree ni n g Visit ( Visit 1) a n d m ust be si g ne d pri or t o perf or ma nce of a n y st u d y-relate d acti vit y.  T he c onse nt f or m t hat is use d m ust be a p pr o ve d b ot h b y t he S p o ns or a n d 
b y t he re vie wi n g I R B or R E C.  T he i nf or me d c o nse nt s h o ul d be i n acc or da nce wit h t he c urre nt 
re visi o n of t he Declarati o n of Helsi n ki, c urre nt I nter nati o nal C o nfere nce o n Har m o nisati o n (I C H) G oo d Cli nical Practice ( G C P) g ui deli nes, a n d S p o ns or p olic y. 
T he I n vesti gat or m ust e x plai n t o p ote ntial s u bjects t he ai ms, met h o ds, reas o na bl y a ntici pate d 
be nefits a n d p ote ntial hazar ds of t he trial a n d a n y disc o mf ort it ma y e ntail.  S u bjects will be i nf or me d t hat t he y are free n ot t o partici pate i n t he trial a n d t hat t he y ma y wit h dra w c o nse nt t o 
partici pate at a n y ti me.  T he y will be t ol d w hic h alter nati ve treat me nts are a vaila ble if t he y ref use 
t o ta ke part, a n d t hat s uc h ref usal will n ot prej u dice f ut ure treat me nt.  Fi nall y, t he y will be t ol d 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422705]'s date d si g nat ure.  If a s u bject is u na ble t o rea d, a n i m partial wit ness m ust be prese nt d uri n g t he e ntire i nf or me d 
c o nse nt disc ussi o n.  T he si g nat ure of t he i m partial wit ness will certif y t he s u bject's c o nse nt.  T he 
s u bject s h o ul d recei ve a si g ne d a n d date d c o p y of t he i nf or me d c o nse nt f or m. 
[ADDRESS_422706] be iss ue d b y t he S p o ns or, si g ne d a n d date d b y t he I n vesti gat or, a n d s h o ul d n ot be i m ple me nte d wit h o ut pri or I R B or R E C  a p pr o val, e xce pt w here necessar y t o 
eli mi nate i m me diate hazar ds t o t he s u bjects or w he n t he c ha n ge(s) i n v ol v es o nl y l o gistical or 
a d mi nistrati ve as pects of t he trial (e. g., c ha n ge i n m o nit or, c ha n ge of tele p h o ne n u m ber).  Res p o nsi bilities f or re p orti n g pr ot oc ol a me n d me nts t o a n y Re g ulat or y A ut h orit y (if a p plica ble) 
a n d/ or I R B or R E C  are f urt her descri be d i n t he Et hical As pects secti o n of t he pr ot oc ol.  
I n sit uati o ns re q uiri n g a de part ure fr o m t he pr ot oc ol, t he I n vesti gat or or ot her p h ysicia n i n 
atte n da nce will c o ntact t he site ma na ger, Me dical M o nit or , or ot her a p pr o priate S p o ns or 
re prese ntati ve b y e mail or tele p ho ne (see S p o ns or C o ntact I nf or mati o n pa ge).  If p ossi ble, t his 
c o ntact will be ma de bef ore i m ple me nti n g a n y de part ure fr o m pr ot oc ol.  I n all cases, c o ntact wit h t he S p o ns or m ust be ma de as s o o n as p ossi ble i n or der t o disc uss t he sit uati o n a n d a gree o n 
a n a p pr o priate c o urse of acti o n.  T he e C R F a n d s o urce d oc u me nt will descri be a n y de part ure 
fr o m t he pr ot oc ol a n d t he circ u msta nces re q uiri n g it. 
[ADDRESS_422707] u d y.   
Esse ntial d oc u me nts i ncl u de, b ut are n ot l i mite d t o:  c urric ul u m vitae f or eac h I n vesti gat or a n d 
s u b-I n vesti gat or, d oc u me ntati o n of I R B/ E C/ R E C pr ot oc ol a p pr o val a n d ass ociate d s u bject 
c o nse nt d oc u me nts, si g ne d cli nical trial a gree me nt, a n d si g ne d pr ot oc ol.  T he S p o ns or or its 
re prese ntati ves will w or k wit h t he sites t o i de ntif y, c ollect, re vie w, a n d a p pr o ve t he a p pr o priate d oc u me ntati o n pac ka ge.   
1 4. 3.  Rec or d Rete nti o n  
I n c o m plia nce wit h t he I C H/ G C P g ui deli nes t he In vesti gat or/i nstit uti o n will mai ntai n all e C R Fs a n d all s o urce d oc u me nts t hat s u p p ort t he data c ollecte d fr o m eac h s u bject, a n d all trial 
d oc u me nts as s pecifie d i n Esse ntial D oc u me nts f or t he C o n d uct of a Cli nical Trial a n d as 
s pecifie d b y t he a p plica ble re g ulat or y re q uire me nt(s).  T he In vesti gat or/i nstit uti o n will ta ke meas ures t o pre ve nt acc i de ntal or pre mat ure destr ucti o n of t hese d oc u me nts.  Esse ntial 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422708].  T hese d oc u me nts will be retai ne d f or a 
l o n ger peri o d if re q uire d b y t he a p plica ble re g ulat or y re q uire me nts or b y a n a gree me nt wit h t he s p o ns or.  It is t he res p o nsi bilit y of t he S p o ns or t o i nf or m t he I n vesti gat or/i nstit uti o n as t o w he n 
t hese d oc u me nts n o l o n ger nee d t o be retai ne d.  If t he res p o nsi ble In vesti gat or retires, rel ocates, 
or f or ot her reas o ns wit h dra ws fr o m t he res p o nsi bilit y of kee pi n g t he st u d y rec or ds, c ust o d y m ust be tra nsferre d t o a pers o n  w h o will acce pt t he res p o nsi bilit y.  T he S p o ns or m ust be n otifie d i n 
writi n g of t he na me a n d a d dress of t he ne w c ust o dia n.  
1 4. 4.  Electr o nic C ase Re p ort F or m  
Electr o nic Case Re p ort F or ms (e C R Fs) will be c o m plete d f or eac h s u bject.  Access f or data e ntr y will be  pr o vi de d t o a p pr o priate site staff me m bers.  All data m ust be e ntere d i nt o t he e C R Fs i n 
E n glis h a n d si g ne d a n d date d electr o nicall y b y t he I n vesti gat or.   
T he e C R Fs s h o ul d be c o m plete d b y I n vesti gat or site staff at t he ti me of t he s u bject's visit, wit h 
t he e xce pti o n of res ults of tests perf or me d o utsi de t he I n vesti gat or's office, s o t hat t he y al wa ys 
reflect t he latest o bser vati o ns o n t he s u bjects partici pati n g i n t he trial.  
As t he site staff e nters data, discre pa ncies will be a ut o maticall y ge nerate d wit hi n t he Electr o nic 
Data Ca pt ure ( E D C) s yste m f or t he site staff t o res ol ve i m me diatel y.  I n a d diti o n, as a res ult of 
data re vie w b y t he S p o ns or or desi g nee, ma n ual q ueries will be raise d electr o nicall y i n t he E D C s yste m.  Q ueries ma y als o be raise d as a res ult of s o urce data verificati o n b y t he cli nical m o nit or.  
All c orrecti o ns will be ma de wit hi n t he E D C s yste m b y t he I n vesti gat or or ot her a ut h orize d st u d y 
site pers o n nel.  T he cli nical m o nit or a n d data ma na ge me nt tea ms will e ns ure a p pr o priate res ol uti o n of q ueries.  T he I n vesti gat or m ust a ut h orize c ha n ges t o t he rec or de d safet y a n d 
efficac y data.  
1 4. 5.  Ter mi n ati o n  
A n i nitiati ve f or ce nter cl os ure or trial ter mi nati o n ca n be ta ke n at a n y ti me eit her b y t he S p o ns or or b y t he I n vesti gat or, pr o vi de d t here is reas o na b le ca use a n d s ufficie nt n otice is gi ve n i n 
a d va nce of t he i nte n de d ter mi nati o n.  Reas o ns f or s uc h acti o n ta ke n b y t he s p o ns or i ncl u de, b ut are n ot li mite d t o: 
•  S uccessf ul c o m pleti o n of t he trial at t he ce nter  
•  T he ma xi m u m n u m ber of eli gi ble s u bjects f or t he trial has bee n e nr olle d •  Fail ure of t he I n vesti gat or t o c o m pl y wit h t he pr ot oc ol, t he S p o ns or's pr oce d ures, or 
G C P g ui deli nes 
•  Safet y c o ncer ns  •  I na de q uate recr uit me nt of s u bjects b y t he I n vesti gat or 
•  B usi ness reas o ns  
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: [ADDRESS_422709] y wit h t his, t he S p o ns or a n d C R O me dical pers o n nel will ha ve t he a bilit y t o re vie w bli n de d safet y 
i nf or mati o n as it is e ntere d a n d verifie d i n t he electr o nic data ca pt ure s yste m (Secti o n  1 4. 4).  
De pe n di n g o n t he e nr oll me nt rate, all A Es i n t he ear a n d la b yri nt h dis or ders S O C will be re vie we d at least e ver y ot her m o nt h.  I n a d diti o n, reas o ns f or st u d y disc o nti n uati o n will be 
re vie we d t o see if a n y tre n ds i n st u d y disc o nti n uati o n are i de ntifie d. 
I n vesti gat ors are i nstr ucte d t o c o ntact Dr u g  Safet y wit hi n 2 4 h o urs f oll o wi n g t he i de ntificati o n of 
a S A E ( Secti o n  9. 2. 2).  All S A Es will be re vie we d b y t he S p o ns or a n d C R O me dical pers o n nel 
wit hi n [ADDRESS_422710] u g.   
T he S p o ns or ass u mes re s p o nsi bilit y f or a p pr o priate re p orti n g t o t he re g ulat or y a ut h orities.  T he In vesti gat or ass u mes res p o nsi bilit y f or re p orti n g e ve nts t o t he I R B or R E C i n acc or da nce wit h 
t he I R B or R E C re q uire me nts.  All S A E’s will be part of t he C R O me dical pers o n nel/S p o ns or 
safet y re vie w. 
If, t hr o u g h t his o n g oi n g re vie w, t he S p o ns or deter mi nes t hat O T O-[ADDRESS_422711]’s me dical rec or ds a n d cli nic c harts, a n d e ns ure t hat t he st u d y is bei n g c o n d ucte d 
acc or di n g t o perti ne nt re g ulat or y re q uire me nts.  T he dates of t he visits will be rec or de d b y t he 
m o nit or i n a trial ce nter visit l o g t o be ke pt at t he site.  T he first p ost -i nitiati o n visit will us uall y be ma de as s o o n as p ossi ble after e nr oll me nt has be g u n.  At t hese visits, t he m o nit or will 
c o m pare t he data e ntere d o nt o t he e C R Fs wit h t he h os pi[INVESTIGATOR_341469] (s o urce d oc u me nts).  
T he re vie w of me dical rec or ds will be perf or me d i n a ma n ner t hat e ns ures s u bject c o nfi de ntialit y is mai ntai ne d.  At a mi ni m u m, s o urce d oc u me ntati o n m ust be a vaila ble t o s u bsta ntiate pr o per 
i nf or me d c o nse nt pr oce d ures, a d here nce t o pr ot oc ol pr oce d ures, a de q uate re p orti n g a n d f oll o w-
u p of A Es, a d mi n istrati o n of c o nc o mita nt me dicati o n, dr u g recei pt/ dis pe nsi n g/ret ur n rec or ds, a n d st u d y dr u g a d mi nistrati o n i nf or mati o n.  S pecific ite ms re q uire d as s o urce d oc u me nts will be 
re vie we d wit h t he I n vesti gat or pri or t o t he st u d y.  Fi n di n gs fr o m t his re vie w of e C R Fs a n d 
s o urce d oc u me nts will be disc usse d wit h t he I n vesti gat or.  T he Sp o ns or e x pects t hat, d uri n g m o nit ori n g visits, t he In vesti gat or (a n d as a p pr o priate, t he st u d y c o or di nat or) will be a vaila ble, 
t he s o urce d oc u me ntati o n will be a vaila ble, a n d a s uita ble e n vir o n me nt will be pr o vi de d f or 
re vie w of st u d y-relate d d oc u me nts. 
[ADDRESS_422712] u d y i nitiati o n, a n d peri o dic m o nit ori n g visits b y t he S p o ns or 
 
 
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 5 7   
 or its re prese ntati ves.  Case re p ort f or ms will be re vie we d f or acc urac y a n d c o m plete ness i n t he 
E D C s yste m data base b y t he S p o ns or or its re prese ntati ves d uri n g a n d after o n- site m o nit ori n g 
visits, a n d a n y discre pa ncies will be res ol ve d wit h t he I n vesti gat or or desi g nees, as a p pr o priate, 
a n d d oc u me nte d i n t he E D C s yste m. 
1 4. 9.  O n -Site A u dits  
Re prese ntati ves of t he S p o ns or's Q ualit y Ass ura nce de part me nt ma y visit t he site t o carr y o ut a n a u dit of t he st u d y i n c o m plia nce wit h re g ulat or y g ui deli nes a n d c o m pa n y p olic y.  S uc h a u dits will re q uire access t o all st u d y rec or ds, i ncl u di n g s o urce d oc u me nts, f or i ns pecti o n a n d 
c o m paris o n wit h t he e C R Fs. S u bject pri vac y m ust, h o we ver, be res pecte d.  S ufficie nt pri or 
n otice will be pr o vi de d t o all o w t he I n vesti gat or t o pre pare  pr o perl y f or t he a u dit.  
Si milar a u diti n g pr oce d ures ma y als o be c o n d ucte d b y a ge nts of a n y re g ulat or y b o d y re vie wi n g 
t he res ults of t his st u d y i n s u p p ort of a Lice nsi n g A p plicati o n.  T he I n vesti gat or s h o ul d 
i m me diatel y n otif y t he S p o ns or if t he y ha ve bee n c o ntacte d b y a re g ulat or y a ge nc y c o ncer ni n g a n u pc o mi n g i ns pecti o n. 
[ADDRESS_422713] u d y a n d will n ot use it  f or ot her p ur p oses wit h o ut t he S p o ns or's writte n 
c o nse nt. 
T he I n vesti gat or u n dersta n ds t hat t he i nf or mati o n de vel o pe d i n t he cli nical st u d y will be use d b y 
t he S p o ns or i n c o n necti o n wit h t he c o nti n ue d de vel o p me nt of O T O- [ADDRESS_422714] u d y will be 
base d o n ge nerall y acce pte d criteria f or maj or me dical j o ur nals.    
Ot o n o m y 1 0 4- 2 0 1 8 1 1 Pr ot oc ol V 3. 0: 3 0 J ul y 2 0 2 0 5 8 1 5. R E F E R E N C E S
A merica n S peec h La n g ua ge Heari n g Ass ociati o n. " G ui deli nes f or Ma n ual P ure- T o ne T hres h ol d
A u di o metr y." as ha. or g. 2 0 0 5. htt p:// w w w.as ha. or g/ p olic y/ G L 2 0 0 5- 0 0 0 1 4. ht m. 
Barritt, La ura. Me niere's Disease. Else vier I nc., 2 0 0 8.  
Cl y de, J ose p h W, Be nja mi n S. O ber ma n, a n d H use yi n Isil da k. “ C urre nt Ma na ge me nt Practices 
i n Me niere’s Disease”. Ot ol o g y & Ne ur ot ol o g y 3 8 ( 2 0 1 7): e 1 5 9- d 1 6 7. 
C o m mittee o n Heari n g a n d E q uili bri u m. “ C o m mittee o n Heari n g a n d E q uili bri u m G ui deli nes f or 
t he dia g n osis a n d e val uati o n of t hera p y i n Me niere’s disease”. Ot olar y n g ol o g y – Hea d 
a n d Nec k S ur ger y 1 1 3 ( 1 9 9 5): 1 8 1- 1 8 5. 
Gates, G A, A M Verrall, J D Gree n, D L T ucci, a n d S A Telia n. " Me niett Cli nical Trial: L o n g -ter m 
F oll o w- u p." Arc hi ves of Ot olar y n g ol o g y - Hea d a n d Nec k S ur ger y 1 3 2 ( 2 0 0 6): 1 3 1 1-1 3 1 6. 
Gates, G A, a n d A M Verrall. " Vali dati o n of t he Mi niere's Di sease Patie nt-Orie nte d S y m pt o m -
Se verit y I n de x." Arc hi ves of Ot olar y n g ol o g y - Hea d a n d nec k S ur ger y 1 3 1 ( 2 0 0 5): 8 6 3-8 6 7. 
Gates, G A, J D Gree n, D L T ucci, a n d S A Telia n. " T he Effects of Tra nst y m pa nic Micr o press ure 
Treat me nt i n Pe o ple wit h U nilateral Me niere's Disease." Arc hi ves of Ot olar y n g ol o g y - Hea d a n d Nec k S ur ger y 1 3 0 ( 2 0 0 4): 7 1 8- 7 2 5. 
Gates, Ge or ge A. " Cli ni metrics of Me niere's Disease." T he Lar y n g osc o pe, 2 0 0 0: 8 - 1 1. 
P os ner, K, G K Br o w n , B Sta nle y, D A Bre nt, K V Yers h o v, M A O q ue n d o, G W C urrier, G A 
Mel vi n, L Gree n hill, S S he n, a n d JJ Ma n n. “ T he C ol u m bia- S uici de Se verit y Rati n g 
Scale: I nitial Vali dit y a n d I nter nal C o nsiste nc y Fi n di n gs fr o m T hree M ultisite St u dies wit h A d olesce nts a n d A d ults.” A merica n J o ur nal of Ps yc hiatr y, 1 6 8 ( 2 0 1 1): 1 2 6 6- 1 2 7 7. 
S hea, J o h n. " Classificati o n of Me niere's Disease." T he A merica n J o ur nal of Ot ol o g y 1 4, n o. 3 
( 1 9 9 3): 2 2 4- 2 2 9. 
T h or nt o n, A, a n d M Raffi n. " S peec h Discri mi nati o n Sc ores M o dele d as a Bi n o mial Varia ble." 
J o ur nal of S peec h a n d Heari n g Researc h 2 1 ( 1 9 7 8): 5 0 7- 5 1 8. 
Ware, J E, K K S n o w, B K osi ns ki, a n d B Ga n de k. S F- 3 6 Healt h S ur ve y: Ma n ual a n d 
I nter pretati o n G ui de. T he Healt h I nstit ute, Ne w E n gla n d Me dical Ce nter, 1 9 9 3. 
Ware, J o h n E. S F- 3 6 P h ysical & Me ntal Healt h S u m mar y Scales: A User’s Ma n ual. Q ualit y 
Metric, 1 9 9 4. 